



(51) International Patent Classification:
C12Q 1/6869 (2018.01)

(21) International Application Number:
PCT/SG2019/050317

(22) International Filing Date:
25 June 2019 (25.06.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10201805450Y 25 June 2018 (25.06.2018) SG

(71) Applicant: **LUCENCE LIFE SCIENCES PTE. LTD.**
[SG/SG]; 211 Henderson Road, #04-02, 211 Henderson Industrial Park, Singapore 159552 (SG).

(72) Inventors: **CHOUDHURY, Yukti**; c/o Lucence Life Sciences Pte. Ltd., 211 Henderson Road, #04-02, 211 Henderson Industrial Park, Singapore 159552 (SG). **CHEN, Hao**; c/o Lucence Life Sciences Pte. Ltd., 211 Henderson Road, #04-02, 211 Henderson Industrial Park, Singapore 159552 (SG). **TAN, Min-Han**; c/o Lucence Life Sciences Pte. Ltd., 211 Henderson Road, #04-02, 211 Henderson Industrial Park, Singapore 159552 (SG).

(74) Agent: **SPRUSON & FERGUSON (ASIA) PTE LTD**;
P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHOD FOR DETECTION AND QUANTIFICATION OF GENETIC ALTERATIONS

(57) Abstract: Disclosed is a method of simultaneously capturing and identifying a defined target region and a partly defined target region within a DNA sample, wherein the partly defined target region comprises a structural variation or rearrangement or fusion. Firstly, a barcoded primer will bind to fragments comprising the defined target region, and another barcoded primer comprising a separation molecule will bind to fragments comprising the partly defined target region. Secondly, the primers that annealed to the defined target region (i.e. product A) are separated from the primers that annealed to the partly defined target region (i.e. product B). Thirdly, the two products are treated differently. For product A, a reverse primer will be added. For product B, a double stranded oligonucleotide is ligated to the end that is not connected to the separation molecule. Fourthly, product A and product B that has been processed are recombined, amplified together, and the resulting amplicons are sequenced.




Figure 1b

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

METHOD FOR DETECTION AND QUANTIFICATION OF GENETIC ALTERATIONS

CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 [0001] This application claims the benefit of priority of Singapore patent application No. 10201805450Y, filed 25 June 2018, the contents of it being hereby incorporated by reference in its entirety for all purposes.

FIELD OF THE INVENTION

- 10 [0002] The present invention relates to the measuring or testing processes involving nucleic acid. In particular, the present invention relates to the detection, quantification, and identification of DNA.

BACKGROUND

- 15 [0003] Detection and quantification of rare genetic events, including low level microbial DNA, is complicated by nature. Typically, high-throughput detection methodologies, which are characterized by an error rate of 0.1-1%, with every 1 of 100 or 1000 bases being called incorrectly due to artifacts introduced during sample preparation and sequencing, are needed to detect and quantify rare genetic events. High-throughput detection methodologies known
20 in the art, however, require repeated sampling or deep sequencing of a large number of molecules, that may not be readily possible due to limitations of sample input amount. To overcome limitations of sample input, the person skilled in the art typically would have to amplify the nucleic acid sequences present in the sample. However, it is generally accepted that amplification methods known in the art are not reliable and do not retain the degree of
25 accuracy demanded for the detection of genomic alterations that occur at extremely low frequencies (i.e. <1%) in the background of otherwise unchanged DNA.

- [0004] Additionally, conventional methods for simultaneously evaluating point mutations, small INDELs and structural variants make use of the hybridization-based approach capture methods which tend to capture off-target regions besides (or in addition to) sequences
30 targeted by capture probes. These off-target regions consume sequencing capacity which is undesirable from the viewpoint of cost-reduction and simplification of analytical methods. Hybridization methods also take much longer for library preparation and have lower

specificity of target capture with off-target regions being captured by the hybridization probes. On the other hand, conventional methods for target capture using forward and reverse primers flanking the target loci, are limited to being able to capture only structural variants with previously known or characterized breakpoints. For the detection of genomic rearrangements with unknown fusion partners, the conventional method (e.g. a pure PCR-based approach) is therefore not applicable. Therefore, there is a need for an alternative method for capturing and identifying distinct targets within a DNA sample. The method should seek to retain specificity of target capture while being able to identify targets of multiple classes.

[0005] Thus, the method of the present invention seeks to impart specificity of target capture while not being limited to capturing target regions with previously known sequence changes. The present invention also seeks to provide an alternative method of detecting and/or quantifying genetic alterations that address reliable detection and a system of verification to ensure errors that occur during amplifications are removed from further processing.

SUMMARY

[0006] In one aspect, the present invention provides a method of simultaneously capturing and identifying distinct targets within a DNA sample, wherein the distinct targets comprise a defined target region and an undefined target region, wherein the undefined target region comprises structural variations or rearrangement or fusion, comprising the steps of:

- a. providing a main mixture comprising a plurality of double stranded DNA fragments A, a plurality of double stranded DNA fragments B, a polymerase, a primer A, and a primer B, wherein:
 - the double stranded DNA fragment A is a double stranded DNA fragment comprising a part of the defined target region;
 - the double stranded DNA fragment B is a double stranded DNA fragment comprising a part of the undefined target region;
 - the primer A comprises, a barcode sequence, and a target-specific sequence A,

wherein the target-specific sequence A is an oligonucleotide complementary to a sequence at/close to the 3' end of a single strand of the double stranded DNA fragment A;

and

- the primer B comprises a separation molecule, a barcode sequence, and a target-specific sequence B,

wherein the target-specific sequence B is an oligonucleotide complementary to a sequence within a single strand of the double stranded DNA fragment B,

- b. denaturing the double stranded DNA fragment A and the double stranded DNA fragment B thereby allowing the primer A to anneal to a single stranded DNA fragment A and the primer B to anneal to the single stranded DNA fragment B;

- c. allowing the polymerase to elongate the primer A and the primer B thereby obtaining a double stranded product A and a double stranded product B, wherein:

- the double stranded product A is a single stranded elongated primer A that is annealed to the single stranded DNA fragment A; and
- the double stranded product B is a single stranded elongated primer B that is annealed to the single stranded DNA fragment B;

- d. adding a bead that binds the separation molecule to the main mixture and allowing the separation molecule in the double stranded product B to bind to the bead thereby forming a double stranded complex B;

- e. separating the double stranded product A and the double stranded complex B in the main mixture thereby obtaining a mixture A and a mixture B, wherein:

- the mixture A comprises the double stranded product A; and
- the mixture B comprises the double stranded complex B;

- f. adding a primer C to the mixture A, wherein the primer C comprises a target-specific sequence C,

wherein the target-specific sequence C is an oligonucleotide complementary to a sequence at/close to the 3' end of the single stranded elongated primer A;

- g. denaturing the double stranded product A in the mixture A thereby allowing the primer C to anneal to the single stranded elongated primer A;
- h. allowing the polymerase to elongate the primer C thereby obtaining a double stranded product C, wherein the double stranded product C is a single stranded elongated primer C that is annealed to the single stranded elongated primer A;
- i. connecting a single nucleotide to the 3' end of the single stranded elongated primer B of the double stranded complex B in the mixture B;
- j. adding a double stranded oligonucleotide to the mixture B wherein the double stranded oligonucleotide comprises a nucleotide overhang complementary to the single nucleotide of step i;
- k. ligating the double stranded oligonucleotide to double stranded complex B at the 3' end of the single stranded elongated primer B and 5' end of the single stranded DNA fragment B thereby obtaining a double stranded product D;
- l. combining the double stranded product C and the double stranded product D;
- m. amplifying the double stranded product C and the double stranded product D thereby obtaining a plurality of amplicons;
- n. sequencing the plurality of amplicons thereby obtaining a plurality of sequencing result;
- o. using the plurality of sequencing results for:
 - identifying single nucleotide sequence variations, or small insertions, or small deletions, or copy number alteration, or deletions of homopolymeric regions, or polymorphism, or microsatellite instability within the defined target regions, or
 - identifying the structural variations within the undefined target regions, or
 - quantifying the number of distinct targets within the DNA sample.

[0007] In one embodiment, the barcode sequence is an oligonucleotide comprising 10 to 16 random nucleotides, or 10 to 15 random nucleotides, or 10 to 13 random nucleotides, or

10 random nucleotides, or 11 random nucleotides, or 12 random nucleotides, or 13 random nucleotides, or 14 random nucleotides, or 15 random nucleotides, or 16 random nucleotides. In another embodiment, the barcode sequence is an oligonucleotide comprising 10 random nucleotides.

5 [0008] In yet another embodiment, the primer A, the primer B, the primer C and/or the double stranded oligonucleotide further comprises an adapter sequence.

[0009] In yet another embodiment, the structural variation is selected from the group consisting of deletion, duplication, insertion, inversion, transversion, and translocation.

10 [0010] In yet another embodiment, the sequencing result is further used to detect a point mutation within the undefined target regions.

[0011] In yet another embodiment, step o further comprises:

- a. grouping the sequencing results wherein the barcodes are identical into a subgroup;
- b. comparing the sequencing results within the subgroup thereby determining a
15 consensus sequence;
- c. mapping the consensus sequence to a reference sequence; and
- d. identifying differences between the consensus sequence and the reference sequence.

20 [0012] In yet another embodiment, the length of the target-specific sequence A, the target-specific sequence B, and/or the target-specific sequence C is from 16 nucleotides to 30 nucleotides, or from 19 nucleotides to 29 nucleotides, or from 20 nucleotides to 28 nucleotides, or from 21 nucleotides to 27 nucleotides, or from 22 nucleotides to 26 nucleotides, or 16 nucleotides, or 17 nucleotides, or 18 nucleotides, or 19 nucleotides, or 20 nucleotides, or 21 nucleotides, or 22 nucleotides, or 23 nucleotides, or 24 nucleotides, or 25
25 nucleotides, or 26 nucleotides, or 27 nucleotides, or 28 nucleotides, or 29 nucleotides, or 30 nucleotides.

[0013] In yet another embodiment, the separation molecule is selected from the group consisting of biotin, digoxigenin (DIG), and Fluorescein isothiocyanate (FITC). In yet another embodiment, the separation molecule is biotin.

30 [0014] In yet another embodiment, the bead that binds the separation molecule comprises streptavidin, anti-digoxigenin, or anti-FITC. In yet another embodiment, the bead that binds the separation molecule comprises streptavidin.

[0015] In yet another embodiment, the DNA sample is obtained from a subject having and/or suspected of having a disease. In yet another embodiment, the disease is cancer or infectious disease. In yet another embodiment, the cancer is selected from the group consisting of lung cancer, colorectal cancer, breast cancer, pancreatic cancer, prostate cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, esophageal cancer, urothelial cancer, and gastrointestinal cancer. In yet another embodiment, the infectious disease is viral infection and bacterial infection.

[0016] In yet another embodiment, the DNA sample is a liquid sample, a tissue sample, or a cell sample. In yet another embodiment, the liquid sample is bodily fluids selected from the group consisting of blood, bone marrow, cerebral spinal fluid, peritoneal fluid, pleural fluid, lymph fluid, ascites, serous fluid, sputum, lacrimal fluid, stool, urine, saliva, ductal fluid from breast, gastric juice, and pancreatic juice. In yet another embodiment, the bodily fluid is blood. In yet another embodiment, the tissue sample is a frozen tissue sample or a fixed tissue sample.

[0017] In yet another embodiment, the length of the DNA fragment A and/or the DNA fragment B is from 80 base pairs to 220 base pairs, or from 90 base pairs to 210 base pairs, or from 100 base pairs to 200 base pairs, or from 110 base pairs to 190 base pairs, or from 120 base pairs to 180 base pairs, or from 130 base pairs to 170 base pairs, or from 140 base pairs to 160 base pairs, or about 80 base pairs, or about 90 base pairs, or about 100 base pairs, or about 110 base pairs, or about 120 base pairs, or about 130 base pairs, or about 140 base pairs, or about 150 base pairs, or about 160 base pairs, or about 170 base pairs, or about 180 base pairs, or about 190 base pairs, or about 200 base pairs, or about 210 base pairs, or about 220 base pairs. In yet another embodiment, the length of the DNA fragment A and/or the DNA fragment B is about 150 base pairs.

[0018] In yet another embodiment, the amount of DNA sample is from 10ng to 200ng, or from 20ng to 190ng, or from 30ng to 180ng, or from 40ng to 170ng, or from 50ng to 160ng, or from 60ng to 150ng, or from 70ng to 140ng, or from 80ng to 130ng, or from 90ng to 120ng, or from 100ng to 110ng, or about 10ng, or about 20ng, or about 30ng, or about 40ng, or about 50ng, or about 60ng, or about 70ng, or about 80ng, or about 90ng, or about 100ng, or about 110ng, or about 120ng, or about 130ng, or about 140ng, or about 150ng, or about 160ng, or about 170ng, or about 180ng, or about 190ng, or about 200ng. In yet another embodiment, the amount of DNA sample is about 100ng.

[0019] In yet another embodiment, the DNA sample is selected from the group consisting of a eukaryotic DNA sample, a prokaryotic DNA sample, a viral DNA sample, and a mixture thereof. In yet another embodiment, the prokaryotic DNA sample is a bacterial DNA sample.

[0020] In yet another embodiment, the eukaryotic DNA sample is selected from the group consisting of a protozoa DNA sample, a fungal DNA sample, an algae DNA sample, a plant DNA sample, and an animal DNA sample. In yet another embodiment, the animal DNA sample is a mammalian DNA sample. In yet another embodiment, the mammalian DNA sample is a human DNA sample. In yet another embodiment, the DNA sample is a cell free DNA or DNA of a lysed cell.

[0021] Advantageously, the method described herein allows for simultaneous capture and identification of both defined target regions and undefined target regions within a DNA sample, which increases efficiency of the detection, quantification, and identification of DNA.

[0022] Advantageously, the method described herein does not require initial splitting of the sample at the target capture step, and a single sample is used for capturing both the defined target region and the undefined target region. Thus, the copy number of the DNA fragments that can be accessed by both the primer that targets the defined target region (i.e. primer A) and the primer that targets the undefined target region (i.e. primer B) is not reduced. Accordingly, the method achieves high sensitivity and specificity.

[0023] Advantageously, the method described herein is able to achieve *simultaneous* detection of: 1) Viral DNA; 2) Microsatellite instability; 3) Structural rearrangements; 4) SNVs and INDELs from samples ranging from cfDNA from plasma (or cerebrospinal fluid, pleural effusion) or DNA from fixed tissue.

[0024] In another aspect, the present invention provides a kit comprising a plurality of primer A as defined herein, a plurality of primer B as defined herein, a plurality of primer C as defined herein, a bead that binds the separation molecule as defined herein, and a double stranded oligonucleotide as defined herein. In yet another embodiment, the kit further comprises a DNA polymerase, a Taq polymerase, a ligase, and a plurality of deoxyribonucleotide triphosphate (dNTPs).

BRIEF DESCRIPTION OF THE DRAWINGS

[0025] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which:

5 [0026] **Figure 1** is a schematic diagram of the method as described herein. That is, **Figure 1a** describes steps a and b of the method as described herein, which are:

a. providing a main mixture comprising a plurality of double stranded DNA fragments A, a plurality of double stranded DNA fragments B, a polymerase, a primer A, and a primer B, wherein:

10 - the double stranded DNA fragment A is a double stranded DNA fragment comprising a part of the defined region;

- the double stranded DNA fragment B is a double stranded DNA fragment comprising a part of the undefined region;

- the primer A comprises, a barcode sequence, and a target-specific sequence A,

15 wherein the target-specific sequence A is an oligonucleotide complementary to a sequence at/close to the 3' end of a single strand of the double stranded DNA fragment A; and

- the primer B comprises a separation molecule, a barcode sequence, and a target-specific sequence B,

20 wherein the target-specific sequence B is an oligonucleotide complementary to a sequence within a single strand of the double stranded DNA fragment B,

b. denaturing the double stranded DNA fragment A and the double stranded DNA fragment B thereby allowing the primer A to anneal to a single stranded DNA fragment A and the primer B to anneal to the a single stranded DNA fragment B.

25 [0027] **Figure 1b** describes steps c to e as follows:

c. allowing the polymerase to elongate the primer A and the primer B thereby obtaining a double stranded product A and a double stranded product B, wherein:

- the double stranded product A is a single stranded elongated primer A that is annealed to the single stranded DNA fragment A and

30 - the double stranded product B is a single stranded elongated primer B that is annealed to the single stranded DNA fragment B;

d. adding a bead that binds the separation molecule to the main mixture and allowing the separation molecule in the double stranded product B to bind to the bead thereby forming a double stranded complex B;

5 e. separating the double stranded product A and the double stranded complex B in the main mixture thereby obtaining a mixture A and a mixture B, wherein:

- the mixture A comprises the double stranded product A and
- the mixture B comprises the double stranded complex B.

[0028] **Figure 1c** illustrates steps f to h as follows:

10 f. adding a primer C to the mixture A, wherein the primer C comprises a target-specific sequence C,

wherein the target-specific sequence C is an oligonucleotide complementary to a sequence at/close to the 3' end of the single stranded elongated primer A;

g. denaturing the double stranded product A in the mixture A thereby allowing the primer C to anneal to the single stranded elongated primer A;

15 h. allowing the polymerase to elongate the primer C thereby obtaining a double stranded product C, wherein the double stranded product C is a single stranded elongated primer C that is annealed to the single stranded elongated primer A.

[0029] **Figure 1d** illustrates the addition of one single nucleic acid overhang, which represents step i as follows:

20 i. connecting a single nucleotide to the 3' end of the single stranded elongated primer B of the double stranded complex B in the mixture B.

[0030] **Figure 1e** illustrates the addition and ligation of double stranded oligonucleotide comprising a nucleic acid that is complementary to the single nucleic acid overhang in Figure 1d (or step i), as follows:

25 j. adding a double stranded oligonucleotide to the mixture B wherein the double stranded oligonucleotide comprises a nucleotide overhang complementary to the single nucleotide of step i;

k. ligating the double stranded oligonucleotide to double stranded complex B at the 3' end of the single stranded elongated primer B and 5' end of the single stranded DNA fragment
30 B thereby obtaining a double stranded product D.

[0031] **Figure 1f** illustrates the sequencing and data processing process of the method as described herein, which refers to steps l to n as follows:

- l. combining the double stranded product C and the double stranded product D;
- m. amplifying the double stranded product C and the double stranded product D thereby obtaining a plurality of amplicons (DNA molecules for sequencing);
- n. sequencing the plurality of amplicons thereby obtaining a plurality of sequencing results;
- o. using the plurality of sequencing results for:
 - identifying single nucleotide sequence variations, or small insertions, or small deletions, or copy number alteration, or deletions of homopolymeric regions, or polymorphism, or microsatellite instability within the defined target regions, or
 - identifying the structural variations within the undefined target regions, or
 - quantifying the number of distinct targets within the DNA sample.

[0032] **Figure 2a** shows illustrative examples of library generation for target amplicons generated from the same starting DNA with both ends being defined by primers. Amplicon generation is achieved by the use of a pair of primers. **Figure 2b** shows illustrative examples of library generation for target amplicons generated from the same starting DNA with only one primer-defined end. Amplicon generation is achieved by the single-ended ligation of a double-stranded oligo adapter.

[0033] **Figure 3a** shows an illustration of the sequencing reads mapping to the reference for amplicons generated with one primer and one ligated adapter. In **Figure 3a** the design of target capture primers is to capture with a multiplicity of primers the region of *ALK* intron 19. These primers correspond to primer B in Figure 1. **Figure 3b** shows an illustration of the sequencing reads mapping to the reference for amplicons generated with both ends defined by primers. In **Figure 3b** the captured region is defined by a pair of primers designed to capture a hotspot region in *ESR1*. The pair of primers corresponds to primer A and primer C from Figure 1.

[0034] **Figure 4a** shows a summary of Variant allele frequency (VAF) observed using the method of the present invention vs. expected frequency of variants in the Horizon Discovery™ cfDNA standards. The amount of DNA used in library preparation was 50-100 ng. **Figure 4b** shows observed frequencies averaged across variants in the Horizon Discovery™ cfDNA standards. **Figure 4c** shows the sensitivity of detection of true variants

in the Horizon Discovery™ cfDNA standards and the specificity reported as the per-base specificity across the target panel (detection of true negatives).

[0035] **Figure 5** shows an example of a primer B, wherein the primer B comprises a separation molecule, an adapter, a barcode, and a target-specific sequence B.

5 [0036] **Figure 6** shows an example of a product A with a very short target captured region shown for illustrative purposes.

[0037] **Figure 7** shows an example of a double stranded oligonucleotide comprising a nucleotide overhang.

[0038] **Figure 8a** shows an example of a Product D, which is obtained when a captured target goes through adapter ligation for amplicon generation as illustrated in Figure 1e. **Figure 8b** shows an example of Product C, which is obtained when a captured target is converted to amplicon with a second primer as shown in Figure 1c.

[0039] **Figure 9** shows an example of the amplification result of either Product C or Product D. Only a single strand of a double-stranded product is shown for illustrative purposes.

[0040] **Figure 10** is an example of using the sequencing results for the detection of fusion. **Figure 10a** is a paired mate mapping for ROS1 gene region known to undergo fusion/rearrangement. The darker and lighter grey reads represent paired reads which have distinct mapping locations in the human genome. The right panel is the region of interest in ROS1 gene with known rearrangement. The left panel is the region that the paired read for the lighter grey read maps to and is identified as SLC34A2. **Figure 10b** shows that the location of the paired read in SLC34A2 is chr4: 256666465, which is a distinct chromosome from the location of ALK which is chr6: 117658151. Thus, **Figure 10** shows that the method of the present invention is able to detect the fusion of *SLC34A2* gene to *ROS1* gene or other genes that are known to undergo rearrangements including fusions.

[0041] **Figure 11a** is a schematic description of a structural variant described as an inversion, at the level of a chromosome. **Figure 11b** is a schematic description of an inversion, compared to the wild-type condition.

[0042] **Figure 12** shows the results of detecting an exemplary inversion in a DNA sample with known inversion variant, using the method of the invention.

[0043] **Figure 13** is a schematic description of a structural variant described as a translocation, at the level of a chromosome.

[0044] **Figure 14** shows the results of detecting an exemplary translocation in a DNA sample with known translocation variant, using the method of the invention.

DETAILED DESCRIPTION

5 [0045] The platform technology allows the simultaneous capture of targeted regions of the human and/or viral genome, as defined by pairs of primers, and of regions not defined by primers pairs, allowing the capture of genomic regions undergoing alterations at unspecified locations within a defined region of interest. In the capture step, a unique molecular tag (i.e. barcode sequence) is attached to each target DNA molecule being captured. The molecular
10 tag (i.e. barcode sequence) allows the tracking of each target DNA fragment as it undergoes sequencing to form a DNA library. The presence of a molecular tag (i.e. barcode sequence) is detected using bioinformatics methods known in the art to count and assign each target DNA sequence from high-throughput sequencing to an original DNA molecule from the sample, carrying the same molecular tag (i.e. barcode sequence). The molecular tags (i.e. barcode
15 sequence) are used to define molecular families, each member of which should carry the exact same sequence unaltered by the processes of capture and conversion to DNA library. Molecular families are then considered together for each region of interest to identify deviations from the expected DNA sequence. Precise deviations in the original nature of DNA sequence are detectable from the application of the 'agreement rule' within molecular
20 families, where lack of agreement among members of each molecular family would result in the entire family being removed from consideration in molecular counts of a region of interest. In the absence of this rule, deviations within molecular families would erroneously lead to the conclusion of a sequence variant, when in fact the disagreement most likely arose from an inevitable process error.

25 [0046] Similarly, tags (i.e. barcode sequence) defining molecular families are also used to determine the number of unique molecules corresponding to each region of interest. Therefore, detection and accurate quantification of rare variants becomes possible through the precise and confident detection of molecules with variant sequence and those without. As exemplified in the Experimental Section, the method as described herein is also capable of
30 detecting non-human genomic sequences such as microbial DNA in a mixture with human DNA.

[0047] The present invention can also be broadly illustrated by the following features. Firstly, a group of primers will bind to DNA fragments comprising the defined (or fully defined) target regions and another group of primers will bind to DNA fragments comprising the undefined (or partly defined) target regions. Secondly, the primers that annealed to the DNA fragments comprising part of the defined target region (i.e. product A) are separated from the primers that annealed to the DNA fragments comprising part of the undefined target region (i.e. product B). Thirdly, upon separation, the two products will undergo two different treatments. For product A, a reverse primer will be added. For product B, a double stranded oligonucleotide is added and ligated to the end that is not connected to the separation molecule that binds the separation beads in an earlier separation step. Fourthly, product A and product B that has been processed are recombined, amplified together, and the resulting amplicons are sequenced.

[0048] The method of the present invention is advantageous because it allows for simultaneous capture and identification of both the defined (or fully defined) target regions and the undefined (or partly defined) target regions (i.e. target regions that are prone to undergo sequence changes which are not previously characterized). The simultaneous capture allows for lesser DNA samples to be used. The reason for having a separate method for the undefined (or partly defined) target regions is that these regions cannot be captured by a pair of primers because the sequence changes can happen at positions within the target that cannot be known when the target capture is being performed (i.e. the precise location and sequence change is unknown). Because the location and the sequence change is unknown, it is not possible to use a pair of primers flanking the target region, as happens in conventional methods. Further, the use of primers and polymerase-mediated extension affords for greater specificity of target capture, compared to conventional methods based on probe hybridization.

[0049] Further to the above, another advantage that the present invention has is that despite separate workflows for converting the defined (or the fully defined) targets and the undefined (or the partly defined) targets into sequencing libraries, the method does not require initial splitting of the sample. By not requiring such splitting, the copy number of the DNA fragments that can be accessed by both the primer that targets the defined target region (i.e. primer A) and the primer that targets the undefined target region (i.e. primer B) is not reduced.

[0050] Thus, in one aspect, the present invention provides a method of simultaneously capturing and identifying distinct targets within a DNA sample, wherein the distinct targets comprise a defined (or a fully defined) target region and an undefined (or a partly defined) target region, wherein the undefined (or the partly defined) target region comprises structural variations or rearrangement or fusion, comprising the steps of:

a. providing a main mixture comprising a plurality of double stranded DNA fragments A, a plurality of double stranded DNA fragments B, a polymerase, a primer A, and a primer B, wherein:

- the double stranded DNA fragment A is a double stranded DNA fragment comprising a part of the defined (or the fully defined) target region;
- the double stranded DNA fragment B is a double stranded DNA fragment comprising a part of the undefined (or the partly defined) target region;
- the primer A comprises, a barcode sequence, and a target-specific sequence A, wherein the target-specific sequence A is an oligonucleotide complementary to a sequence at/close to the 3' end of a single strand of the double stranded DNA fragment A;

and

- the primer B comprises a separation molecule, a barcode sequence, and a target-specific sequence B,

wherein the target-specific sequence B is an oligonucleotide complementary to a sequence within a single strand of the double stranded DNA fragment B,

b. denaturing the double stranded DNA fragment A and the double stranded DNA fragment B thereby allowing the primer A to anneal to a single stranded DNA fragment A and the primer B to anneal to the a single stranded DNA fragment B;

c. allowing the polymerase to elongate the primer A and the primer B thereby obtaining a double stranded product A and a double stranded product B, wherein:

- the double stranded product A is a single stranded elongated primer A that is annealed to the single stranded DNA fragment A and
- the double stranded product B is a single stranded elongated primer B that is annealed to the single stranded DNA fragment B;

- d. adding a bead that binds the separation molecule to the main mixture and allowing the separation molecule in the double stranded product B to bind to the bead thereby forming a double stranded complex B;
- e. separating the double stranded product A and the double stranded complex B in the main mixture thereby obtaining a mixture A and a mixture B, wherein:
- the mixture A comprises the double stranded product A and
 - the mixture B comprises the double stranded complex B;
- f. adding a primer C to the mixture A, wherein the primer C comprises a target-specific sequence C,
- wherein the target-specific sequence C is an oligonucleotide complementary to a sequence at/close to the 3' end of the single stranded elongated primer A;
- g. denaturing the double stranded product A in the mixture A thereby allowing the primer C to anneal to the single stranded elongated primer A;
- h. allowing the polymerase to elongate the primer C thereby obtaining a double stranded product C, wherein the double stranded product C is a single stranded elongated primer C that is annealed to the single stranded elongated primer A;
- i. connecting a single nucleotide to the 3' end of the single stranded elongated primer B of the double stranded complex B in the mixture B;
- j. adding a double stranded oligonucleotide to the mixture B wherein the double stranded oligonucleotide comprises a nucleotide overhang complementary to the single nucleotide of step i;
- k. ligating the double stranded oligonucleotide to double stranded complex B at the 3' end of the single stranded elongated primer B and 5' end of the single stranded DNA fragment B thereby obtaining a double stranded product D;
- l. combining the double stranded product C and the double stranded product D;
- m. amplifying the double stranded product C and the double stranded product D thereby obtaining a plurality of amplicons (or DNA molecules for sequencing);

- n. sequencing the plurality of amplicons thereby obtaining a plurality of sequencing result;
- o. using the plurality of sequencing results for:
 - identifying single nucleotide sequence variations, or small insertions, or small deletions, or copy number alteration, or deletions of homopolymeric regions, or polymorphism, or microsatellite instability within the defined (or the fully defined) target regions, or
 - identifying the structural variations within the undefined (or the partly defined) target regions, or
 - quantifying the number of distinct targets within the DNA sample.

[0051] In one example, the present invention provides a method of simultaneously identifying a defined region and an undefined region within a DNA sample, wherein the undefined region comprises a structural variation, comprising the steps of:

a. providing a main mixture comprising a plurality of double stranded DNA fragments A, a plurality of double stranded DNA fragments B, a polymerase, a primer A, and a primer B, wherein:

- the double stranded DNA fragment A is a double stranded DNA fragment comprising a part of the defined region;

- the double stranded DNA fragment B is a double stranded DNA fragment comprising a part of the undefined region;

- the primer A comprises, a barcode sequence, and a target-specific sequence A, wherein the target-specific sequence A is an oligonucleotide complementary to a sequence at/close to the 3' end of a single strand of the double stranded DNA fragment A; and

- the primer B comprises a separation molecule, a barcode sequence, and a target-specific sequence B,

wherein the target-specific sequence B is an oligonucleotide complementary to a sequence within a single strand of the double stranded DNA fragment B,

b. denaturing the double stranded DNA fragment A and the double stranded DNA fragment B thereby allowing the primer A to anneal to a single stranded DNA fragment A and the primer B to anneal to the a single stranded DNA fragment B;

c. allowing the polymerase to elongate the primer A and the primer B thereby obtaining a double stranded product A and a double stranded product B, wherein:

- the double stranded product A is a single stranded elongated primer A that is annealed to the single stranded DNA fragment A and

5 - the double stranded product B is a single stranded elongated primer B that is annealed to the single stranded DNA fragment B;

d. adding a bead that binds the separation molecule to the main mixture and allowing the separation molecule in the double stranded product B to bind to the bead thereby forming a double stranded complex B;

10 e. separating the double stranded product A and the double stranded complex B in the main mixture thereby obtaining a mixture A and a mixture B, wherein:

- the mixture A comprises the double stranded product A and

- the mixture B comprises the double stranded complex B;

f. adding a primer C to the mixture A, wherein the primer C comprises a target-
15 specific sequence C,

wherein the target-specific sequence C is an oligonucleotide complementary to a sequence at/close to the 3' end of the single stranded elongated primer A;

g. denaturing the double stranded product A in the mixture A thereby allowing the primer C to anneal to the single stranded elongated primer A;

20 h. allowing the polymerase to elongate the primer C thereby obtaining a double stranded product C, wherein the double stranded product C is a single stranded elongated primer C that is annealed to the single stranded elongated primer A;

i. connecting a single nucleotide to the 3' end of the single stranded elongated primer B of the double stranded complex B in the mixture B;

25 j. adding a double stranded oligonucleotide to the mixture B wherein the double stranded oligonucleotide comprises a nucleotide overhang complementary to the single nucleotide of step i;

k. ligating the double stranded oligonucleotide to double stranded complex B at the 3' end of the single stranded elongated primer B and 5' end of the single stranded DNA fragment
30 B thereby obtaining a double stranded product D;

l. combining the double stranded product C and the double stranded product D;

m. amplifying the double stranded product C and the double stranded product D thereby obtaining a plurality of amplicons (or DNA molecules for sequencing);

n. sequencing the plurality of amplicons thereby obtaining a plurality of sequencing results;

- 5 o. using the plurality of sequencing results for:
- identifying single nucleotide sequence variations, or small insertions, or small deletions, or copy number alteration, or deletions of homopolymeric regions, or polymorphism, or microsatellite instability within the defined target regions, or
 - 10 - identifying the structural variations within the undefined target regions, or
 - quantifying the number of distinct targets within the DNA sample.

[0052] For example, the method as described herein is illustrated by the schematic diagrams presented in Figure 1. That is, Figure 1a describes steps a and b of the method as described herein, which are:

15 a. providing a main mixture comprising a plurality of DNA fragments A, a plurality of DNA fragments B, a polymerase, a primer A, and a primer B, wherein:

- the DNA fragment A is a DNA fragment comprising a part of the defined region;
- the DNA fragment B is a DNA fragment comprising a part of the undefined region;
- the primer A comprises, a barcode sequence, and a target-specific sequence A,

20 wherein the target-specific sequence A is an oligonucleotide complementary to a sequence at/close to the 3' end of a DNA fragment A; and

- the primer B comprises a separation molecule, a barcode sequence, and a target-specific sequence B,

25 wherein the target-specific sequence B is an oligonucleotide complementary to a sequence within a DNA fragment B,

b. denaturing the DNA fragment A and the DNA fragment B thereby allowing the primer A to anneal to a DNA fragment A and the primer B to anneal to the DNA fragment B.

[0053] Figure 1b describes steps c to e as follows:

30 c. allowing the polymerase to elongate the primer A and the primer B thereby obtaining a double stranded product A and a double stranded product B, wherein:

- the double stranded product A is a single stranded elongated primer A that is annealed to the DNA fragment A and

- the double stranded product B is a single stranded elongated primer B that is annealed to the DNA fragment B;

d. adding a bead that binds the separation molecule to the main mixture and allowing the separation molecule in the double stranded product B to bind to the bead thereby forming a double stranded complex B;

e. separating the double stranded product A and the double stranded complex B in the main mixture thereby obtaining a mixture A and a mixture B, wherein:

- the mixture A comprises the double stranded product A and

- the mixture B comprises the double stranded complex B.

[0054] Figure 1c illustrates steps f to h as follows:

f. adding a primer C to the mixture A, wherein the primer C comprises a target-specific sequence C,

wherein the target-specific sequence C is an oligonucleotide complementary to a sequence at/close to the 3' end of the single stranded elongated primer A;

g. denaturing the double stranded product A in the mixture A thereby allowing the primer C to anneal to the single stranded elongated primer A;

h. allowing the polymerase to elongate the primer C thereby obtaining a double stranded product C, wherein the double stranded product C is a single stranded elongated primer C that is annealed to the single stranded elongated primer A.

[0055] Figure 1d illustrates the addition of one single nucleic acid overhang, which represents step I as follows:

i. connecting a single nucleotide to the 3' end of the single stranded elongated primer B of the double stranded complex B in the mixture B.

[0056] Figure 1e illustrates the addition and ligation of double stranded oligonucleotide comprising a nucleic acid that is complementary to the single nucleic acid overhang in Figure 1d (or step i), as follows:

j. adding a double stranded oligonucleotide to the mixture B wherein the double stranded oligonucleotide comprises a nucleotide overhang complementary to the single nucleotide of step i;

k. ligating the double stranded oligonucleotide to double stranded complex B at the 3' end of the single stranded elongated primer B and 5' end of the single stranded DNA fragment B thereby obtaining a double stranded product D.

[0057] Figure 1f illustrates the sequencing and data processing process of the method as described herein, which refers to steps l to n as follows:

- l. combining the double stranded product C and the double stranded product D;
- m. amplifying the double stranded product C and the double stranded product D
- 5 thereby obtaining a plurality of amplicons (or DNA molecules for sequencing);
- n. sequencing the plurality of amplicons thereby obtaining a plurality of sequencing result;
- o. using the plurality of sequencing results for:
 - identifying single nucleotide sequence variations, or small insertions, or
 - 10 small deletions, or copy number alteration, or deletions of homopolymeric regions, or polymorphism, or microsatellite instability within the defined target regions, or
 - identifying the structural variations within the undefined target regions, or
 - quantifying the number of distinct targets within the DNA sample.

[0058] As used herein, the term “**defined region**” is defined as a region in a DNA fragment that is free of structural variations that may be found in the undefined region (i.e. structural variations that are not previously characterized). That is, the “**defined region**” comprises a region of DNA fragment that structurally is identical to or substantially the same as DNA fragments from a reference sequence. In other words, a “fully defined target region”

15 is a target for which the sequence identity (i.e. the start and end of the target) are fully defined prior to capture. In the present disclosure, the term “defined region”, “defined target region”, and “fully defined target region” are used interchangeably. Thus, it would be understood by the person skilled in the art that the term “**undefined region**” would encompass a region of DNA fragment that has structural variations that are not previously characterized. In other

20 words, “partly defined target region” is a target for which the sequence identity is not fully defined prior to target capture and comprises target region prone to undergo sequence changes (such as structural rearrangements). It is appreciated that the precise sequence composition of a “partly defined target region” cannot be predetermined and thus it may be impossible to design a pair of defining primers for such region. The sequence definition of an

25 “undefined region”, or a “partly defined target region”, such as detection of genomic rearrangements with unknown fusion partners, is determinable only once the sequencing results are obtained. It would also be apparent to the person skilled in the art that the defined

30

region and undefined region would have different DNA sequences. Thus, in some examples, the target specific sequence A and the target specific sequence B do not overlap. As would be understood by the person skilled in the art, the term “undefined target region” does not mean that 100% of the DNA sequence within the target region is unknown in the art. As used
5 herein, the “undefined target region” refers to a target region wherein about 5%, or about 10%, or about 20%, or about 30%, or about 40%, or about 50%, or about 60%, or about 70%, or about 80%, or about 90%, or about 95% of the DNA sequence within the target region is unknown in the art. In the present disclosure, the term “undefined region”, “undefined target region”, and “partly defined target region” are used interchangeably. As used herein, the term
10 “**barcode sequence**” is a commonly used term in the art of nucleic acid sequencing and used within the definition as known in the art. Thus, the term “**barcode sequence**” refers to the encoded molecules or barcodes that include variable amount of information within the nucleic acid sequence. For example, the barcode sequence is a tag that can be read out using any of a variety of sequence identification techniques, for example, nucleic acid sequencing,
15 probe hybridization based assay, and the like. In some examples, the barcode sequence is used in the method as described herein to append different target specific sequences, such that when the barcode sequence and target specific sequence anneal to the (target) DNA fragment, each different (target) DNA fragment would then have a unique barcode sequence that is attached to it and read out with the sequence of the (target) DNA fragment from that
20 sample. The barcode sequence allows the pooled analysis of multiple unique DNA fragments, where the resulting sequence information from the pool can be later attributed back to each starting DNA fragment. That is, after the process of amplification, the barcode sequence is used to group amplicons to form a family of amplicons having the same oligonucleotide with a randomly assigned nucleic acid sequence (i.e. same barcode oligonucleotide). In some
25 examples, the barcode sequence is an overhang that does not complement any sequence within DNA fragment A and DNA fragment B. In some examples, the barcode sequence may be an oligonucleotide comprising 10 to 16 random nucleotides, or 10 to 15 random nucleotides, or 10 to 13 random nucleotides, or 8 random nucleotides, or 11 random nucleotides, or 12 random nucleotides, or 13 random nucleotides, or 14 random nucleotides,
30 or 15 random nucleotides, or 16 random nucleotides. In one example, the barcode sequence is an oligonucleotide comprising 10 random nucleotides. As exemplified in the Experimental Section, the barcode sequence may be defined as NNNNNNNNNN (SEQ ID NO: 1), which

may have the sequences such as, but is not limited to, CATTACATAC (SEQ ID NO: 2), GCGTGGACAA (SEQ ID NO: 3), TTTT TAGACA (SEQ ID NO: 4), TAAGAGGTCC (SEQ ID NO: 5), and the like.

[0059] As used herein, the term “**at the 3’ end**” corresponds to the last nucleotide of a single DNA strand. As used herein, the term “**close to the 3’ end**” corresponds to a distance of from 1 to 100 nucleotides, or from 5 to 90 nucleotides, or from 10 to 80 nucleotides, or from 15 to 70 nucleotides, or from 20 to 60 nucleotides, or about 1 nucleotides, or about 5 nucleotides, or about 10 nucleotides, or about 15 nucleotides, or about 20 nucleotides, or about 25 nucleotides, or about 30 nucleotides, or about 35 nucleotides, or about 40 nucleotides, or about 50 nucleotides, or about 60 nucleotides, or about 70 nucleotides, or about 80 nucleotides, or about 90 nucleotides, or about 100 nucleotides from the 3’ end of a single DNA strand. In one example, when the term “close to the 3’ end” is used to define a reverse primer, the binding site of the reverse primer (for example, primer C) is predetermined such that the overall length of the target region defined by combination of the forward primer (for example primer A) and the reverse primer is from 80 base pairs (bp) to 200 bp, or from 100 bp to 180 bp, or from 120 bp to 160 bp, or from 140 bp to 150 bp, or about 80 bp, or about 90 bp, or about 100 bp, or about 110 bp, or about 120 bp, or about 130 bp, or about 140 bp, or about 150 bp, or about 160 bp, or about 170 bp, or about 190 bp, or about 200 bp.

[0060] In regard to step i of the present invention (i.e. the step of connecting a single nucleotide to the 3’ end of the single stranded elongated primer B of the double stranded complex B in the mixture B), a person skilled in the art is aware that the single nucleotide that is to be connected with the 3’ end of the single stranded elongated primer B can be any nucleotide. In one example, the single nucleotide may include, but is not limited to, adenine (A), cytosine (C), guanine (G), thymine (T), and the like. In one example, wherein when the single nucleotide to be connected is adenine (A), Taq polymerase is used and the connecting step is known as “A-tailing”. The A-tailing step exploits the intrinsic terminal transferase activity of Taq polymerase by which it catalyzes the template-independent addition of an adenine residue to the 3’ end of both strands of DNA molecules. In the presence of a mixture of four dNTPs, dA is added preferentially to 3’ end of DNA molecule by Taq polymerase. Other nucleotides can be added but would require differing reaction conditions for Taq

activity. Therefore, under standard reaction conditions, in the presence of dNTPs, Taq polymerase will preferentially incorporate dA to the 3' end of the DNA molecules.

[0061] As the method as described herein utilises sequencing platforms/methods known in the art, it would be apparent to the person skilled in the art that the DNA fragment processed through the steps of the method as described herein may have to be prepared to comprise additional nucleic acid sequences recognised by the sequencing platforms/methods (i.e. adapter sequences). Thus, in some examples, the primer A, the primer B, the primer C and/or the double stranded oligonucleotide further comprises an adapter sequence.

[0062] As used herein, the term “**adapter sequence**” refers to an oligonucleotide sequence bound to the 5' and 3' end of each DNA fragment in a sequencing library. The adapter sequences are complementary to the plurality of oligonucleotide present on the surface of flow cells of the sequencing tools thereby allowing the DNA fragment to attach to the sequencing tools. In some examples, when the sequencing utilized is Illumina Sequencing (i.e. Illumina® sequencing technology), the adapter may be a universal P5 adapter as follows: AATGATACGGCGACCACCGAGATCT (SEQ ID NO: 13), and/or an indexed P7 adapter as follows: CAAGCAGAAGACGGCATACGAGAT (SEQ ID NO: 14) (see **Table 1**).

[0063] As described herein, the distinct targets within the DNA sample that can be simultaneously captured and identified by the method of the present comprises a defined target region (or a fully defined target region) and an undefined target region (or a partly defined target region). In one example, the undefined target region (or the partly defined target region) comprises structural variations or rearrangement or fusion, which are not previously characterized. In one example, the undefined target region (or the partly defined target region) is prone to undergo a structural rearrangement or sequence changes. As used herein, the term “**structural variations**” refers to variations in the structure of the genome – i.e. in the **order** of sections of the DNA (as opposed to the smaller variation to the sequence alone which maintains the overall order to the DNA sections with respect to the genome). As used herein, the term “**rearrangement**” refers to - rearrangements in the order of sections of the DNA (interchangeable with “structural variations”). As used herein, the term “**fusion**” refers to structural variants produced through interchromosomal or intrachromosomal rearrangements. In one example, the structural variations may include, but are not limited to, deletion, duplication, insertion, inversion, transversion, translocation, and the like. As used herein, the term “**deletion**” refers to a sequence change where more than 50 nucleotides are

removed. As used herein, the term “**duplication**” refers to a sequence change where a copy of one or more nucleotides are inserted directly 3'-flanking of the original copy. As used herein, the term “**insertion**” refers to a sequence change where more than 50 nucleotides are inserted between two nucleotides but where the insertion is not a copy of a sequence immediately 5'-flanking. As used herein, the term “**inversion**” refers to a sequence change where more than one nucleotide replacing the original sequence are the reverse complement of the original sequence. As used herein, the term “**translocation**” refers to rearrangement of parts between non-homologous chromosomes, which can result in “fusion”.

[0064] As would be apparent to the person skilled in the art, the method as described herein can also be used to detect single nucleotide variations such as substitution. In some examples, the sequencing result is further used to detect a single nucleotide variation. In some examples, the sequencing result is further used to detect a single nucleotide variation within the undefined target region (or the partly defined target region). In some examples, the sequencing result is further used to detect a single nucleotide variation within the defined target region (or the fully defined target region). As used herein, the term “**single nucleotide variation**”, “**single nucleotide sequence variation**”, and “**point mutation**” may be used interchangeably.

[0065] In one example, the defined target region (or the fully defined target region) comprises single nucleotide sequence variations, small insertion, small deletion, genomic copy number alteration, deletion of homopolymeric region, foreign DNA sequences (e.g. wherein the DNA sample is human DNA, microbial DNA sequences are considered foreign DNA sequence), polymorphisms or single-nucleotide variations in microbial DNA sequence, and the like. In one example, the deletion of homopolymeric region may include but is not limited to microsatellite instability. As used herein, the term “**single nucleotide sequence variations**” or “**single nucleotide variations**” refers to variation in a single nucleotide that occurs at a specific position in the genome, differing from the nucleotide defining the position in the reference genome. As used herein, the term “**small insertion**” refers to a sequence change where less than 50 nucleotides are inserted between two nucleotides but where the insertion is not a copy of a sequence immediately 5'-flanking. As used herein, the term “**small deletion**” refers to a sequence change where less than 50 nucleotides are removed. As used herein, the term “**copy number alteration**” refers to the repetition of sections of the genome (duplication) or loss of sections of the genome (deletion). As used

herein, the term “**deletions of homopolymeric regions**” refers to the shortening of a homopolymeric tracts in the genome. An example of “deletions of homopolymeric region” is GCGAAAAAAAAAAAAAAAAATA becomes GCGAAATA, this a deletion of 12 A’s from the the homopolymeric tract of 15 A’s. As used herein, the term “**polymorphism**” refers to a variation in a single nucleotide that occurs at a specific position in the genome, and is a variation in all copies of the organism’s genome, differing from nucleotide defining the position in the organism’s population (reference). As used herein, the term “**microsatellite instability**” refers to genetic instability in short nucleotide repeats or microsatellite, which is a tract of tandemly repeated (i.e. adjacent) DNA motif ranging from one to six or up to ten nucleotides, with each motif repeated 5 to 50 repeated times. A person skilled in the art is aware that the sum of all of the variants within the defined target region (or the fully defined target region) is known as total mutation (or variant) load or tumour mutational burden (TMB). A person skilled in the art is also aware that determining the total mutation (or variant) load or tumour mutational burden (TMB) is useful in determining the therapeutic target of certain diseases (such as cancer).

[0066] The method of the present disclosure can also be used to detect certain diseases. Thus, in one example, the DNA sample for the method of the present disclosure is obtained from a subject having and/or suspected of having a disease. In some examples, the disease may include, but is not limited to cancer, infectious disease, and the like. In some examples, the cancer may include, but is not limited to, lung cancer, colorectal cancer, breast cancer, pancreatic cancer, prostate cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, esophageal cancer, urothelial cancer, gastrointestinal cancer, and the like. In some examples, the infectious diseases may include, but is not limited to, viral infection, bacterial infection, and the like.

[0067] To reduce false positive alterations that typically arise in amplification process, the barcode sequences used in the method as described herein can be used to form subgroups of sequences and to arrive at consensus sequences that are then used for further analysis or determination of whether mutation is truly present in the target DNA fragments. Thus, in some examples, step n further comprises:

- grouping the sequencing results wherein the barcode sequences are identical, into a subgroup;

- comparing the sequencing results within the subgroup thereby determining a consensus sequence;
 - mapping the consensus sequence to a reference sequence; and
 - identifying differences between the consensus sequence and the reference
- 5 sequence to analyse and determine whether mutation is truly present in the target DNA fragments.

In one example, the mutation may be single nucleotide variations. In another example, the mutation may be small INDELs. In another example, the mutation may be microsatellite instability.

10 [0068] As used herein, the term “**reference sequence**” refers to nucleotide sequences (such as DNA sequences or RNA sequences) known in the art that may be obtainable from public databases.

[0069] As used herein, the term “**consensus sequence**” refers to a nucleotide sequence obtained from consensus calling. In one example, consensus calling is performed by

15 identifying the nucleotide at each position for each sequencing result within the subgroup, comparing the identity for the nucleotide at each position across the plurality of sequencing results, and determining a majority nucleotide at each position. If the majority nucleotide count is above a threshold set for determining majority for specific position, the assignment for said position is the majority nucleotide. If the majority nucleotide count is below this

20 threshold, no assignment is made for said position. The threshold is variable for every position and is a function of the total number of sequencing results corresponding to a specific position.

[0070] In some examples, the length of the target-specific sequence A, the target-specific sequence B, and/or the target-specific sequence C is from 17 nucleotides to 31 nucleotides, or

25 from 19 nucleotides to 29 nucleotides, or from 20 nucleotides to 28 nucleotides, or from 21 nucleotides to 27 nucleotides, or from 22 nucleotides to 26 nucleotides, or 18 nucleotides, or 19 nucleotides, or 20 nucleotides, or 21 nucleotides, or 22 nucleotides, or 23 nucleotides, or 24 nucleotides, or 25 nucleotides, or 26 nucleotides, or 27 nucleotides, or 28 nucleotides, or 29 nucleotides, or 30 nucleotides. In some examples, the length of the target-specific

30 sequence A, the target-specific sequence B, and/or the target-specific sequence C is 22 nucleotides. A person skilled in the art is also aware that in order to determine the length of the primer A, the primer B, the primer C, the target-specific sequence A, the target-specific

sequence B, and/or the target-specific sequence C, he will have to also consider other primer properties including, but not limited to, melting temperature (or T_m), GC-content (or guanine-cytosine content or GC%) and propensity of a primer to dimerize with other primers and itself.

5 [0071] As used herein, a “**separation molecule**” refers to a tag or molecule that is capable of binding to a bead to thereby allow for the separation of the nucleotide that is connected to the separation molecule. As illustrated in Figure 1b or Figure 1d, the separation molecule may be, but is not limited to biotin, digoxigenin (DIG), Fluorescein isothiocyanate (FITC), and the like. In some examples, the separation molecule is biotin. In consequence, to capture
10 the separation molecule, the bead that binds to the separation molecule may comprise, but is not limited to a substrate linked with streptavidin, anti-digoxigenin, anti-FITC, and the like. In one example, the bead that binds to the separation molecule comprises magnetic beads linked to streptavidin. In some examples, the bead that binds to the separation molecule may be magnetic beads that have been functionalized with streptavidin, anti-digoxigenin, anti-
15 FITC, and the like.

[0072] In addition, the method as described herein is compatible with multiple sources of DNA material, including circulating DNA from blood plasma or cerebrospinal fluid (CSF), fragmented formalin-fixed paraffin embedded DNA (FFPE DNA), genomic DNA from leukocytes and from other cells. The method as described herein could also cover more than
20 50 targeted genes, over 500 targeted regions in the human genome and 15 DNA virus families, and is readily expandable for future inclusion of target regions. As the sequencing library is based on the use of primers for the capture of target regions, it works with equivalent specifications on multiple sample types such as circulating DNA and FFPE DNA. For example, primer-based capture of FFPE DNA is not hindered by fragmentation, as long
25 as the expected amplicon size as defined by primers is limited to a reasonably short length of about 160-bp. Up to eight classes of target regions such as single-nucleotide variations or fusions can also be simultaneously captured using the first set of primers from a single sample of DNA. Following the primer-based capture, steps are taken for the completion of amplicons or ends with sequencing adapters and final amplification before high-throughput
30 sequencing. The combination of primer and PCR-based methods for sequencing analysis allows for a smaller input DNA to be worked with without losing sensitivity. As such, the inventors of the present disclosure envisaged that the method as described herein can be

performed in a liquid sample or tissue sample. Thus, in some examples, the sample is a liquid sample, a tissue sample, or a cell sample.

[0073] In some examples, the liquid sample may include, but is not limited to, bodily fluids such as, but is not limited to, blood, bone marrow, cerebral spinal fluid, peritoneal fluid, pleural fluid, lymph fluid, ascites, serous fluid, sputum, lacrimal fluid, stool, urine, saliva, ductal fluid from breast, gastric juice, pancreatic juice, and the like. In one example, the bodily fluid is blood. The liquid sample that is useful for the method of the present technology is a liquid that comprises DNA which is circulating and not contained within cells (or cell free DNA). The DNA within the liquid can be isolated from the liquid in a form that is free from impurities (or pure form).

[0074] In some examples, the tissue sample may include, but is not limited to frozen tissue sample, fixed tissue sample (such as formalin-fixed tissue sample).

[0075] The method of the present invention is optimized for DNA fragments having certain sizes. A person skilled in the art is aware that when the DNA sample comprises full-length DNA, the full-length DNA can be processed and fragmented to certain length that is suitable for the method of the present invention. In some examples, the length of the DNA fragment A and/or the DNA fragment B is from 80 base pairs to 220 base pairs, or from 90 base pairs to 210 base pairs, or from 100 base pairs to 200 base pairs, or from 110 base pairs to 190 base pairs, or from 120 base pairs to 180 base pairs, or from 130 base pairs to 170 base pairs, or from 140 base pairs to 160 base pairs, or about 80 base pairs, or about 90 base pairs, or about 100 base pairs, or about 110 base pairs, or about 120 base pairs, or about 130 base pairs, or about 140 base pairs, or about 150 base pairs, or about 160 base pairs, or about 170 base pairs, or about 180 base pairs, or about 190 base pairs, or about 200 base pairs, or about 210 base pairs, or about 220 base pairs. In one example, the length of the DNA fragment A and/or the DNA fragment B is about 150 base pairs.

[0076] Since primers are used to detect target defined or undefined regions, the inventors found the method as described herein to be useful in detecting small DNA sample. Thus, in some examples, the amount of DNA sample may be from 10ng to 200ng, or from 20ng to 190ng, or from 30ng to 180ng, or from 40ng to 170ng, or from 50ng to 160ng, or from 60ng to 150ng, or from 70ng to 140ng, or from 80ng to 130ng, or from 90ng to 120ng, or from 100ng to 110ng, or about 10ng, or about 20ng, or about 30ng, or about 40ng, or about 50ng, or about 60ng, or about 70ng, or about 80ng, or about 90ng, or about 100ng, or about 110ng,

or about 120ng, or about 130ng, or about 140ng, or about 150ng, or about 160ng, or about 170ng, or about 180ng, or about 190ng, or about 200ng. In some examples, the amount of DNA sample is about 100ng.

[0077] Since the method as described herein can be used to detect undefined region that comprises structural variations that are not previously characterized, the DNA sample to be used in the method as described herein may include, but is not limited to, a eukaryotic DNA sample, a prokaryotic DNA sample, a viral DNA sample, and a mixture thereof. In some examples, the prokaryotic DNA sample is a bacterial DNA sample. In some examples, the eukaryotic DNA sample may include, but is not limited to, a protozoa DNA sample, a fungal DNA sample, an algae DNA sample, a plant DNA sample, an animal DNA sample, and the like. In some examples, the animal DNA sample is a mammalian DNA sample (such as human DNA sample). In some examples, the DNA sample may be a cell free DNA or DNA of a lysed cell.

[0078] In another aspect, the present invention provides for a kit comprising a plurality of primer A as defined herein, a plurality of primer B as defined herein, a plurality of primer C as defined herein, a bead that binds the separation molecule as defined herein, and a double stranded oligonucleotide as defined herein. In some examples, the kit of the present invention further comprises a DNA polymerase, a Taq polymerase, a ligase, a plurality of deoxyribonucleotide triphosphate (dNTPs). In some examples, the reagents provided in the kit as described herein may be provided in separate containers comprising the components independently distributed in one or more containers. As the method as described herein relates to sequencing (such as high-throughput sequencing), further components required in sequencing processes could be easily determined by the person skilled in the art.

[0079] As used in this application, the singular form “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a primer” includes a plurality of primers, including mixtures and combinations thereof.

[0080] As used herein, the terms “increase” and “decrease” refer to the relative alteration of a chosen trait or characteristic in a subset of a population in comparison to the same trait or characteristic as present in the whole population. An increase thus indicates a change on a positive scale, whereas a decrease indicates a change on a negative scale. The term “change”, as used herein, also refers to the difference between a chosen trait or characteristic of an

isolated population subset in comparison to the same trait or characteristic in the population as a whole. However, this term is without valuation of the difference seen.

[0081] As used herein, the term "about" in the context of concentration of a substance, size of a substance, length of time, or other stated values means +/- 5% of the stated value, or +/- 4% of the stated value, or +/- 3% of the stated value, or +/- 2% of the stated value, or +/- 1% of the stated value, or +/- 0.5% of the stated value.

[0082] Throughout this disclosure, certain embodiments may be disclosed in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0083] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms "comprising", "including", "containing", etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the inventions embodied herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.

[0084] The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

[0085] Other embodiments are within the following claims and non-limiting examples. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

5

EXPERIMENTAL SECTION

EXAMPLES

[0086] **Material**

[0087] **Exemplary molecular tag complex or primers when target is EGFR-exon18_1**

10 [0088] An example of a “primer” when the target sequence is EGFR-exon 18_1 (an example of primer A, illustrated in Figure 1a) is as follows:

ACACGACGCTCTTCCGATCT**NNNNNNNNNN**GGTGACCCTTGTCTCTGTGTTC (SEQ ID NO: 6), wherein the bases in italic and underline are an example of adapter sequence, the bases in bold represent the barcode sequence and the bases in underline is an example of target specific sequence.

15

[0089] An example of subsequent primers for the “completion of amplicon” (an example of primer C, illustrated in Figure 1c) is as follows:

GACGTGTGCTCTTCCGATCTGAGCCCAGCACTTTGATCTTTTT (SEQ ID NO: 7), where bases in underline are target-specific primers.

20

[0090] Expected amplicon (only target-specific region)

>chr7:55173886+55174018 133bp
GGTGACCCTTGTCTCTGTGTTCGAGCCCAGCACTTTGATCTTTTTGGTGACCCTTG
TCTCTGTGTTCttgtccccccagcttggagcctcttacaccagtggaagaagctcccaaccaagctctcttgaggatcttg
aaggaaactgaattcAAAAAGATCAAAGTGCTGGGCTC (SEQ ID NO: 8)

25

[0091] **Product after amplicon completion (in two steps)** (Only one strand of the double stranded product is shown.):

ACACGACGCTCTTCCGATCTNNNNNNNNNNGGTGACCCTTGTCTCTGTGTTCttgtcc
ccccagcttggagcctcttacaccagtggaagaagctcccaaccaagctctcttgaggatcttgaaggaaactgaattcAAAA
AGATCAAAGTGCTGGGCTCAGATCGGAAGAGCACACGTC (SEQ ID NO: 9), where

30

the bases in underline is target nucleic acid.

Universal amplification primer 1 (an example of the primer for amplifying product C or D):

AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGA
TC*T (SEQ ID NO: 10)

Universal amplification primer 2 (indexed) (an example of the primer for amplifying product
5 C or D, the index is the bases in bold and italic font):

CAAGCAGAAGACGGCATACGAGATAT***CACGGT***GACTGGAGTTCAGACGTGTGCT
CTTCCGATC*T (SEQ ID NO: 11)

[0092] **Final product (suitable for sequencing on Illumina)**

10 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGA
TCTNNNNNNNNNNNGGTGACCCTTGTCTCTGTGTT**Cttgtccccccagcttgtggagcctttacaccc**
agtggagaagctcccaaccaagctctcttgaggatcttgaaggaaactgaattcAAAAAGATCAAAGTGCTGGGC
TC
AGATCGGAAGAGCACACGTCTGAACTCCAGTCACCGTGATATCTCGTATGCCGTC
15 TTCTGCTTG (SEQ ID NO: 12), where the bases in underline is target nucleic acid.

[0093] **Methods**

[0094] ***DNA library generation***

[0095] The workflow for preparing DNA library is divided into three major steps. In the
20 first step (**Figure 1a**), **target DNA were captured** using a multiplex pool of primers. Each
primer is a molecular tag complex comprising an oligonucleotide with 10 random nucleotides
(a molecular tag/barcode sequence) linked to a target-specific primer, which functions in
target capture. Some of the primers in primer pool for target capture are 5' biotin-labeled (B).
An example of the primer that is biotin-labeled is shown on **Figure 5**.

25 [0096] Briefly, in a 50 µl reaction, 10-100 ng of DNA was mixed with a primer pool in
which each primer was at 0.05-0.2 µM, 0.2 mM of dNTPs, 0.5-1.5 mM MgSO₄, 0.6 units of
KOD enzyme and reaction buffer. Target capture and enrichment was done using the
following thermocycling conditions: Denaturation at 94°C for 1 min, followed by **1 to 3**
cycles of 98°C for 1 min, 60° to 65° C for 6 mins, and 68°C for 5 mins. The length of the
30 targets captured was dictated by the length of the template DNA fragment, and the extension
time allowed, such that a variety of target lengths would be captured in this first step. Three
cycles were allowed to compensate for less than 100% efficiency of primer binding to targets,

so as to increase target capture. At the end of this reaction, each captured target DNA had a random molecular tag linked to it. Excess unused primers were removed by purification with 1.5x AMPure XP beads in two rounds. This means eluate from the first round of purification was bound to 1.5x beads and subjected to a second round of purification. Final elution was done in 10 to 30 µl of buffer EB.

[0097] **Product after step 1 (examples of Product A and Complex B, illustrated in Figure 1b):**

[0098] An example with a very short target captured region shown for illustrative purposes is shown on **Figure 6**.

[0099] In the second step (**Figures 1b-1e**), targets with defined (specified) ends and those with undefined ends were subjected to distinct treatments to **complete** the structure of a **target-specific amplicon** which could then be amplified to generate a sequencing platform-specific DNA library molecule. Before this could be done, targets with undefined ends were separated from other targets using the biotin tags incorporated in the target capture primers. Briefly, the 10 to 30 µl eluate from step 1 (target capture) was mixed with an equal volume of washed MyOne Streptavidin C1 beads, and the bead mix was allowed to incubate at room temperature with intermittent mixing for 1 hour to allow the binding of biotin to streptavidin. With this step, target DNA that were captured with biotin-labeled primers become immobilized on the streptavidin-coated beads. Meanwhile, target DNA captured with unlabeled primers remain in the supernatant (or bead solution mix). At the end of one hour, the supernatant containing target DNA captured with unlabeled primers were collected separately, and the target DNA captured with biotin-labeled primers were on beads, thus achieving separation of captured DNA intended for different treatments in step 2 for **amplicon-generation**.

[00100] Targets captured on beads were washed briefly with bead wash (B&W) solution, followed by “on-bead” A-tailing reaction. Briefly, the beads with immobilized targets were resuspended in 10ul reaction mixture containing 6.4µl water, 1µl 10X buffer for KOD-Plus-Neo, 1µl of 2mM dNTPs, 0.6µl of 25mM MgSO₄, and 1µl of 10X A-attachment mix (Toyobo Co., Ltd., Japan). The beads were incubated at 60°C for 10 mins to allow A-tailing of the captured, immobilized DNA targets. The beads were washed again with 1x B&W buffer. Following this, the beads were resuspended in a ligation mix to allow “on-bead” ligation of a ds-oligo partial adapter. Briefly, beads were resuspended in a 10µl reaction mix

containing 5µl of Blunt/TA ligase master mix (NEB, USA), 4µl of water, and 1µl of 10µM adapter with a 3' T overhang. An example of a 3' T overhang is shown for example on **Figure 7** (the 3' T overhang is bolded and underlined).

[00101] The mixture was incubated at 25°C for 1 hr, with intermittent shaking. At the end of hours, the mixture was chilled on ice. The beads were then washed three times with 1X B&W buffer. At the end of this step, target DNA captured on the beads would have undergone amplicon-generation by the one-sided ligation of the partial adapter. Adapter ligation on the other (immobilized) end was inhibited due to the overhang tail introduced during target capture, and the presence of biotin-streptavidin complex. Finally, the completed amplicons were eluted from the streptavidin beads by disrupting the biotin-streptavidin bonds, by incubating the beads in 10 µl of elution solution (10mM EDTA pH 8.2 and 95% formamide) at 65°C for 5 mins to elute biotin labelled targets from the beads. The eluate was collected following magnetic separation of streptavidin beads. The eluate containing captured DNA targets (**converted to amplicons**) was collected and purified once with 1.5x AMPure XP beads to remove the formamide solution and replace it with EB buffer. DNA was eluted in 11.5 µl Buffer EB.

[00102] Targets that were not captured on streptavidin beads, as they lacked biotin tags, were first purified once with 1.5x AMPure XP beads to replace the B&W buffer with sample buffer. DNA was eluted in 23 µl of Buffer EB. Amplicon-generation was then done using a multiplex pool of “reverse” target-specific primers. Briefly, in a 50 µl reaction, purified DNA from target capture step is mixed with a primer pool in which each primer is at 0.05-0.2 µM, 0.5-1.5 mM of dNTPs, 1.5 nM MgSO₄, 1 unit of KOD enzyme and reaction buffer. **Amplicon generation** was done using the following thermocycling conditions: Denaturation at 94°C for 1 min, followed by **1 to 3** cycles of 98°C for 1 min, 60°C for 6 mins, and 68°C for 5 mins. The completed amplicons were purified twice from the PCR mix with 1.5x AMPure beads. DNA was eluted in 11.5 µl Buffer EB. An example of the **product after step 2** if target captured goes through adapter ligation for amplicon generation is shown on **Figure 8a** and an example of the **product after step 2** if target captured is converted to amplicon with a second primer is shown on **Figure 8b**.

[00103] In the third step (**Figure 1f**), a final amplification was performed to amplify the targets and to complete the library structure required for sequencing on the Illumina platform, by introducing sequencing adapters. Briefly, the purified targets (amplicons from step 2),

both with defined (specified) ends and those with undefined (unknown) ends from the starting DNA material are recombined and pooled into one final PCR reaction. Briefly, 23 μ l of combined DNA (11.5 μ l from each procedure for biotin-labeled and unlabeled targets) is mixed with 1 μ l of 5-20 μ M universal P5 adapter

5 (AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCT, P5 sequence is underlined), 1 μ l of 5-20 μ M indexed P7 adapter (**Table 1**) and KAPA HiFi HotStart ReadyMix in a 50 μ l reaction. The PCR was carried out with the following profile: Denaturation at 98°C for 45 s, followed by **22-26** cycles of 98°C for 15 s, 60°C for 30 s, and 72°C for 30 s, with a final extension at 72°C for 1 min. The amplified library was

10 purified twice with 0.6-0.8x AMPure XP beads to remove non-specific products. The quality and quantity of the sequencing library was assessed using the 4200 TapeStation system (Agilent Technologies, USA) and KAPA Library Quantification Kit for Illumina® Platforms (Kapa Biosystems Inc., USA) respectively. An Example of the product after step 3 is shown on **Figure 9**.

15 [00104] Libraries were multiplexed and paired-end sequencing (2x150 bp) was done following manufacturer's instructions.

[00105] **Table 1**

P7 adapter	Sequence (P7 adapter sequence is italicized and the sample indexes are in bold underline)
R_ID1 (SEQ ID NO: 15)	<i>CAAGCAGAAGACGGCATACTGAGATATC<u>ACGGT</u>GACTGGAGTTC</i> <i>AGACGTGTGCTCTTCCGATCT</i>
R_ID2 (SEQ ID NO: 16)	<i>CAAGCAGAAGACGGCATACTGAGAT<u>CGATGT</u>GACTGGAGTTC</i> <i>AGACGTGTGCTCTTCCGATCT</i>
R_ID3 (SEQ ID NO: 17)	<i>CAAGCAGAAGACGGCATACTGAGATT<u>TAGGCG</u>TGACTGGAGTTC</i> <i>AGACGTGTGCTCTTCCGATCT</i>
R_ID4 (SEQ ID NO: 18)	<i>CAAGCAGAAGACGGCATACTGAGATT<u>GACCA</u>GACTGGAGTTC</i> <i>AGACGTGTGCTCTTCCGATCT</i>
R_ID5 (SEQ ID NO: 19)	<i>CAAGCAGAAGACGGCATACTGAGAT<u>ACAGTGG</u>TGACTGGAGTTC</i> <i>AGACGTGTGCTCTTCCGATCT</i>
R_ID6 (SEQ ID NO: 20)	<i>CAAGCAGAAGACGGCATACTGAGAT<u>GCCAAT</u>TGACTGGAGTTC</i> <i>AGACGTGTGCTCTTCCGATCT</i>
R_ID7	<i>CAAGCAGAAGACGGCATACTGAGAT<u>CAGATC</u>TGACTGGAGTTC</i>

(SEQ ID NO: 21)	AGACGTGTGCTCTTCCGATCT
R_ID8	CAAGCAGAAGACGGCATACGAGAT <u>ACTTG</u> AGTGACTGGAGTTC
(SEQ ID NO: 22)	AGACGTGTGCTCTTCCGATCT
R_ID9	CAAGCAGAAGACGGCATACGAGAT <u>GATCAG</u> GTGACTGGAGTTC
(SEQ ID NO: 23)	AGACGTGTGCTCTTCCGATCT
R_ID10	CAAGCAGAAGACGGCATACGAGAT <u>TAGCTT</u> GTGACTGGAGTTC
(SEQ ID NO: 24)	AGACGTGTGCTCTTCCGATCT
R_ID11	CAAGCAGAAGACGGCATACGAGAT <u>GGCTAC</u> GTGACTGGAGTTC
(SEQ ID NO: 25)	AGACGTGTGCTCTTCCGATCT
R_ID12	CAAGCAGAAGACGGCATACGAGAT <u>CTTGTA</u> GTGACTGGAGTTC
(SEQ ID NO: 26)	AGACGTGTGCTCTTCCGATCT
R_ID13	CAAGCAGAAGACGGCATACGAGAT <u>AGTCAAG</u> TGACTGGAGTTC
(SEQ ID NO: 27)	AGACGTGTGCTCTTCCGATCT
R_ID14	CAAGCAGAAGACGGCATACGAGAT <u>AGTTCCG</u> TGACTGGAGTTC
(SEQ ID NO: 28)	AGACGTGTGCTCTTCCGATCT

[00106] **Data analysis**

[00107] FASTQ files were processed using a custom pipeline. First, expected amplicons were identified and labeled in the FASTQ files based on the expected primer sequences in Read 1 and paired Read 2. For amplicons with one unknown end, only primers in Read 1 were used for identification and labeling. Primer sequences and upstream molecular tag sequences were trimmed using cutadapt, primer trimmed sequences were mapped to the reference genome using bwa-mem. For “primer” trimmed fastq files, the name of the primer which had the best match to a read was concatenated to the name of the mapped output reads (for both Read 1 and Read 2). The primer name assigned to Read 1 might not always match that of Read 2, which could be due to overlapping amplicons or non-specific binding. An “amplicon_name” was assigned to each paired read by combining the matching primer name of Read 1 and Read 2 (concatenated by semicolon).

[00108] Molecular tag (or barcode) sequences were included in the trimmed “primer” sequences of Read 1, and could be extracted given the unique structure of primer sequences in Read 1. The extracted molecular tag sequences are clustered in two steps: 1. Initial grouping by exact match of the combination of amplicon_name + barcode sequence and 2.

Cluster Reassignment, in each group of same amplicon_name, barcodes were further reassigned using global pairwise alignment with maximum 2 base differences between barcodes. Barcode clusters with number of associated reads less than 3 (after cluster reassignment) were considered unreliable clusters and removed from downstream analysis.

5 [00109] Consensus Calling was done for each molecular tag (or barcode) cluster, by first performing global alignment among all associated reads using MAFFT. The consensus base in each aligned position was called by determining the majority representative base type, the percentage of which is no less than an automatically determined threshold. The threshold was a function of the total number of reads for that barcode sequence. If no representative base
10 could be called, the position was assigned N (as opposed to one of A, C, T, G). A new quality score was assigned to each position, which was either 90th percentile of all the quality values from the representative base type in that position (if a consensus base was found), or 10th percentile of all quality values in that position (if no consensus bases was found). The consensus reads were written to a new FASTQ file. An exemplary result of the consensus
15 reads mapped to the reference is shown on **Figure 3**.

[00110] The consensus FASTQ files were mapped to the reference genome, with local realignment to improve mapping. Read depth was calculated from the mapped BAM file in the target regions in the specified .bed file (of expected amplicons or regions). Variant calling was performed on consensus BAM files using Mutect2, lofreq and a custom variant caller.
20 Exemplary result of the library generation is shown on **Figure 2**.

[00111] Exemplary results for variant detection and frequency of clinical samples are shown on **Table 2** and exemplary results for detection of Epstein Barr Virus (EBV) microbial DNA targets in clinical samples are shown on **Table 3**. To generate the results in **Table 2** and **Table 3**, clinical samples which have been previously characterized for EGFR mutations
25 (positive or negative) and EBV DNA (present or absent) by orthogonal methods (such as Quantitative PCR) were identified. Cell-free DNA (cfDNA) was extracted from the same samples which had been selected to have had sufficient plasma. The extracted cfDNA was quantified and processed with the method as described herein to determine if similar results of detection (of EGFR mutations and EBV DNA) with orthogonal methods (such as
30 Quantitative PCR) could be achieved. **Tables 2** and **3** summarize the findings of orthogonal methods (such as Quantitative PCR) presented together with findings from the method as described herein. As can be seen in **Table 2**, 16 clinical samples (plasma) were tested by the

method as described herein and by quantitative PCR, respectively, for detection of EGFR mutations (such as small nucleotide variants, and small INDELs) and determination of the frequency of mutations. The result showed 98% concordance of mutation detection and agreement of mutant allele frequency by both methods. The sample numbers in the first column of Table 2 which showed concordance between the conventional method (quantitative PCR) and the method of the present invention are: 1, 2, 3, 4, 5 (for L858R), 6, 7, 8, 9, 10, 11 (for EGFR c.2236_2250del), 12, 13, 14, 15 (for E746_A750delELRA and EGFR T790M), and 16 (for KRAS G12D). In addition, in contrast to quantitative PCR, which is used to detect various mutations in separate reactions (each reaction is used to detect one mutation, i.e. each row in column 2 (labeled "Mutation reported by AS-PCR") of Table 2 corresponds to one single reaction), the method of present invention is able to simultaneously detect multiple mutations in the same sample, in one single reaction (i.e. all the mutations listed in all the rows in column 6 (labeled "Variant identified by Hallmark") of Table 2 are detected in one single reaction). As can be seen in **Table 3**, detection of Epstein Barr Virus (EBV) microbial DNA targets BamHI-W and EBNA1, in clinical samples (plasma) by the method as described herein and quantitative PCR showed 89% concordance of detection. The sample numbers in the first column of Table 3 which showed concordance between the conventional method (quantitative PCR) and the method of the present invention are: 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34 and 35. Additionally, mutations in human DNA were detected. Also, in serial samples from the same individual, matched mutations (such as small nucleotide variants, and small INDELs) were present. Serial samples from the same individual are depicted within a black box and are shaded in grey. Thus, the method of the present inventions is able to simultaneously detect viral DNA and mutations in human DNA. In addition, in contrast to quantitative PCR, which is used to detect various mutations and the viral DNA in separate reactions (each reaction is used to detect one mutation or viral DNA, i.e. each row in column 2 (labeled "EBV BamHI-W") of Table 3 corresponds to one single reaction), the method of present invention is able to simultaneously detect multiple mutations in human DNA and the viral DNA in the same sample, in one single reaction (i.e. all the mutations listed in all the rows in column 11 (labeled "Mutations") of Table 3 are detected in one single reaction).

Table 2. Mutation detection and frequency in 16 clinical samples (plasma) tested by the method of the present invention and by quantitative PCR.

Quantitative PCR		The method of the present invention							
Sample	Mutation reported by AS-PCR	Frequency reported by AS-PCR	Amount of DNA used for library preparation (ng)	Theoretical DNA copies available for conversion	Variant identified by Hallmark	Total consensus read depth	Variant consensus read depth	Frequency	Concordance
1	EGFR L858R	1.10%	4.65	1534	EGFR L858R	243	6	2.47%	Yes
2	EGFR L858R	3.95%	9.02	2977	EGFR L858R	288.00	7	2.43%	Yes
	EGFR T790M	3.15%			EGFR T790M	284	10	3.52%	Yes
3	EGFR E746_A750del	>5%	20.00	6600	EGFR E746_A750del (c.2235_2249del)	1936	1464	75.62%	Yes
	EGFR T790M	>5%			EGFR T790M	2313	150	6.49%	Yes
4	EGFR L858R	1-5%	5.96	1967	L858R	478	9	1.88%	Yes
5	EGFR T790M	0.10%	7.99	2637	T790M	362	0	ND	No
					L858R	730	2	0.27%	Yes
6	EGFR E746_A750del	1.07%	12.08	3988	EGFR E746_A750del	876	22	2.51%	Yes
7	EGFR E746_A750del	>5%	13.40	4422	EGFR E746_A750del	800	42	5.25%	Yes
8	E746_A750del	1.06%	15.50	5114	EGFR E746_A750del	796	10	1.26%	Yes
9	E746_A750del	0.27%	13.46	4442	EGFR E746_A750del	744	4	0.54%	Yes
10	unspecified	>5%	20.00	6600	EGFR	1842	188	10.21%	Yes

Table 3. Detection of Epstein Barr Virus (EBV) microbial DNA targets BamHI-W and EBNA1, in clinical samples (plasma) by the method of the present invention and qPCR.

Quantitative PCR			The method of the present invention											
Sam ple	EBV BamHI-W	EBV IU/mL	Amount of DNA (ng)	Vo l. of inp ut DN A (ul)	Num ber of total read s	Number of BamHI- W1 (consensu s paired read mean depth)	Num ber of Bam H1- W-2	EB NA- 1-1	EB NA- 1-2	Mutations	Total read depth	Variant read depth	Frequenc y	Conc ordan ce
17	21434 copies/mL	2146 IU/mL	11.25	26. 4	1139 942	451	151	16	0	KIT c.1621A>C p.Met541Leu	57	26	45.61	Yes
18	1150 copies/mL	115 IU/mL	50	5.8	3628 698	0	0	0	0	VHL c.556G>A p.Glu186Lys APC c.4351G>A p.Glu1451Lys APC c.848G>A p.Arg283Gln PTEN c.961G>A p.Ala321Thr	1393 3544 692 590	8 5 3 4	0.57 0.43 0.68	No
19	4715 copies/mL	472 IU/mL	9.19	26. 4	8534 78	72	38	8	0	PIK3CA c.929G>A p.Arg310His PTEN c.511C>G p.Leu171Val	264 362	4 182	1.52 50.28	Yes
20	4772 copies/mL	478 IU/mL	50	24. 5	4592 289	104	46	12	0	APC c.4435G>A p.Val1479Ile	556	3	0.54	Yes

21	81371 copies/mL	8147 IU/mL	35	21. 4	3830 404	1776	984	146	0					Yes
22	2169 copies/mL	217 IU/mL	6.54	4 4	5639 57	344	128	0	0					Yes
23	4606 copies/mL	461 IU/mL	7.66	4 4	6100 17	272	98	2	0					Yes
24	>12,500,000 copies/mL	>1,251,539 IU/mL	100	7.7	1139 394	7335.824	1261. 985	55	5	TP53 c.488A>G p.Tyr163Cys	827	6		Yes
25	7,928,069 copies/mL	793,783 IU/mL	75	21. 4	5708 489	330336	8707 1	197 93	214	APC c.647G>A p.Arg216Gln TP53 c.488A>G p.Tyr163Cys ERBB2 c.308G>A p.Arg103Gln MED12 c.127C>A p.Gln43Lys	3653 1907 5450 2102	5 7 8 2	0.14 0.37 0.15 0.10	Yes
26	>12,500,000 copies/mL	>1,251,539 IU/mL	100	7.7	5776 267	187656	4186 4	316 0	135	TP53 c.488A>G p.Tyr163Cys MED12 c.127C>A p.Gln43Lys ERBB2 c.308G>A p.Arg103Gln	1918 3085 8419	6 8 6	0.31 0.26 0.07	Yes
27	4,676,723 copies/mL	468,248 IU/mL	38	21. 4	4999 232	214665	5918 8	995 4	314	TP53 c.488A>G p.Tyr163Cys ESR1	1519 27576	16 14	1.05 0.05	Yes

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

[00112] Exemplary result for the summary of Variant allele frequency (VAF) observed using the method of the present invention vs. standards is shown on **Figure 4**.

[00113] Exemplary use of the sequencing results obtained using the method of the present invention for the detection of *fusion* is shown in **Figure 10**. The process for detection of fusion as shown in Figure 10 is described as follows:

(1) A sample was obtained from cell line DNA with known structural variations, for the purpose of validating the method of the present invention. The DNA was fragmented to generate fragments with sizes ranging from 20-400 bp;

(2) The fragmented DNA (100 ng) underwent conversion to sequencing library as described in the methods described in paragraph [00100]. An appropriate primer pool was used in the initial target capture such that primers for the capture of a broad region of ROS1 known to undergo structural variations were included in the target capture;

(3) Sequencing and data analysis was performed according to the methods described in the section of "Data Analysis" above;

(4) Mapped reads were inspected in Integrated genome Viewer (IGV) for the presence of a) soft-clip, b) insertions and/or 3) mapping of Reads 1 and 2 of a paired sequencing read to physically separated regions of the genome. Two or more such supporting paired reads carrying the breakpoint or mapping to distant regions of genome were required to support the call for structural variant. The "partner" of the structural variant was identified by the mate read location or by aligning (BLASTing) an insertion or soft-clip sequence against the human genome to identify the origin of the insertion sequence.

[00114] The above process may be used for detecting structural variation in any target region known to undergo structural variation without prior knowledge of the precise location of the breakpoint. The above process may also be applied to DNA from fixed tissue (which is already fragmented to varying degrees) or cfDNA from plasma, pleural fluid or cerebrospinal fluid.

[00115] In addition, examples of other types of structural variants which may be detected using the above mentioned process are:

[00116] ***Inversion***

[00117] An example of detection of a structural variant described as an inversion, in which a DNA sequence is reversed end to end, is shown in **Figure 11(a)** at the level of a chromosome.

[00118] The resulting inversion in a smaller target region of interest is represented in **Figure 11(b)**, with sequence directionality indicated by arrows in wild-type condition and in the condition with the inversion. The inversion may involve a large part of the genome or a relatively small part resulting in two breakpoints.

5 [00119] An example of an inversion involving a region of chromosome 9 with breakpoints determined at exactly chr9:5,467,953 and chr9:6,557,405, was detected by the method of the invention (**Figure 12**). The inversion shown in **Figure 12** is one which results in a portion of genome from chr9:6,557,405 to become adjacent in inverted form to chr9: chr9:5,467,953. **Figure 12** depicts paired reads from sequencing results, Reads 1 and 2, which map to
10 different non-contiguous locations of the genome, as derived from the mapping of the reads sequence.

[00120] ***Translocation***

[00121] An example of a translocation involving a region of chromosome 6 and chromosome 4 is shown in **Figure 13**. Breakpoints are deducible from sequencing results
15 obtained by the method of the invention. **Figure 14** depicts paired reads from sequencing results, Reads 1 and 2, which map to different non-contiguous locations of the genome, as derived from the mapping of the reads sequence.

[00122] In principle, any of the following listed types of other structural variants:

20 *-duplication;*

-insertion;

-transversion;

are detectable by the method of the invention, as long as a breakpoint in a target region of interest is captured among the sequencing reads. The non-contiguous nature of the alignment of the sequencing read allows for the detection of any form of structural variant. In other
25 words, as long as the method of the invention incorporates capture primers/probes for a target region of interest known to undergo any one of the structural variations mentioned above, that type of structural variant can be detected. This is because, once sequencing reads are available, detection of structural variants may be done by the alignment of the reads to two different non-contiguous parts of the genome. Based on the method of the invention, it is not
30 critical that the non-contiguous part of the read comes from the same chromosome and is inverted (i.e. inversion) or from another chromosome (i.e. translocation).

[00123] **Comparison of the method of the invention to conventional methods**

[00124] Compared to conventional methods of next-generation sequencing using hybridization capture of targets or primer-based amplicon capture, the performance of the method of the invention is comparable to the conventional methods for detection of various types of genomic alterations, as established during the development and validation phase of the method (please refer to Tables 2 and 3). As can be seen in Table 4 below, the method of the invention achieved more than 99% sensitivity and specificity for detecting small nucleotide variations (SNVs) at all the mutant allele frequency tested; more than >83.3% sensitivity and specificity for detecting INDELs at 0.1% mutant allele frequency and more than 99% sensitivity and specificity for detecting INDELs at 1%, 5% and 10% mutant allele frequency tested; more than >50% sensitivity and specificity for detecting fusions at 1% mutant allele frequency and more than 99% sensitivity and specificity for detecting fusions at 5% and 10% mutant allele frequency tested. In addition, the various mutations listed in Figure 4 are detected by the method of the present invention simultaneously, in one single reaction.

MUTANT ALLELE FREQUENCY		0.1%		1%		5%		10%	
		Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity
Mutation Class	SNVs	>99%	>99%	>99%	>99%	>99%	>99%	>99%	>99%
	INDELs	>83.3%	>99%	>99%	>99%	>99%	>99%	>99%	>99%
	Fusions	-	-	>50%	>99%	>90%	>99%	>90%	>99%

Table 4. Sensitivity and specificity of the method of the invention for the detection of various kinds of mutations.

[00125] In addition, compared to the conventional methods, the method of the invention possesses unexpected advantages. For example, the method of the invention is able to achieve simultaneous detection of: 1) Viral DNA; 2) Microsatellite instability; 3) Structural rearrangements; 4) SNVs and INDELs from samples ranging from cfDNA from plasma (or cerebrospinal fluid, pleural effusion) or DNA from fixed tissue.

[00126] Compared to the method of the invention, conventional methods do not allow for the simultaneous detection of these genomic alteration types or are not amenable to function with multiples sources of DNA.

Claims

1. A method of simultaneously capturing and identifying distinct targets within a DNA sample, wherein the distinct targets comprise a defined target region and an
5 undefined target region, wherein the undefined target region comprises structural variations or rearrangement or fusion, comprising the steps of:
- a. providing a main mixture comprising a plurality of double stranded DNA fragments A, a plurality of double stranded DNA fragments B, a polymerase, a primer A, and a primer B, wherein:
- 10 - the double stranded DNA fragment A is a double stranded DNA fragment comprising a part of the defined target region;
- the double stranded DNA fragment B is a double stranded DNA fragment comprising a part of the undefined target region;
- the primer A comprises, a barcode sequence, and a target-specific
15 sequence A,
wherein the target-specific sequence A is an oligonucleotide complementary to a sequence at/close to the 3' end of a single strand of the double stranded DNA fragment A;
- and
- 20 - the primer B comprises a separation molecule, a barcode sequence, and a target-specific sequence B,
wherein the target-specific sequence B is an oligonucleotide complementary to a sequence within a single strand of the double stranded DNA fragment B,
- 25 b. denaturing the double stranded DNA fragment A and the double stranded DNA fragment B thereby allowing the primer A to anneal to a single stranded DNA fragment A and the primer B to anneal to the single stranded DNA fragment B;
- c. allowing the polymerase to elongate the primer A and the primer B thereby
30 obtaining a double stranded product A and a double stranded product B,
wherein:
- the double stranded product A is a single stranded elongated primer A that is annealed to the single stranded DNA fragment A; and

- the double stranded product B is a single stranded elongated primer B that is annealed to the single stranded DNA fragment B;
- d. adding a bead that binds the separation molecule in the main mixture and allowing the separation molecule in the double stranded product B to bind to the bead thereby forming a double stranded complex B;
- e. separating the double stranded product A and the double stranded complex B in the main mixture thereby obtaining a mixture A and a mixture B, wherein:
 - the mixture A comprises the double stranded product A and
 - the mixture B comprises the double stranded complex B;
- f. adding a primer C to the mixture A, wherein the primer C comprises a target-specific sequence C,
 - wherein the target-specific sequence C is an oligonucleotide complementary to a sequence at/close to the 3' end of the single stranded elongated primer A;
- g. denaturing the double stranded product A in the mixture A thereby allowing the primer C to anneal to the single stranded elongated primer A;
- h. allowing the polymerase to elongate the primer C thereby obtaining a double stranded product C, wherein the double stranded product C is a single stranded elongated primer C that is annealed to the single stranded elongated primer A;
- i. connecting a single nucleotide to the 3' end of the single stranded elongated primer B of the double stranded complex B in the mixture B;
- j. adding a double stranded oligonucleotide to the mixture B wherein the double stranded oligonucleotide comprises a nucleotide overhang complementary to the single nucleotide of step i;
- k. ligating the double stranded oligonucleotide to double stranded complex B at the 3' end of the single stranded elongated primer B and 5' end of the single stranded DNA fragment B thereby obtaining a double stranded product D;
- l. combining the double stranded product C and the double stranded product D;

- m. amplifying the double stranded product C and the double stranded product D thereby obtaining a plurality of amplicons;
- n. sequencing the plurality of amplicons thereby obtaining a plurality of sequencing result;
- 5 o. using the plurality of sequencing results for:
- identifying single nucleotide sequence variations, or small insertions, or small deletions, or copy number alteration, or deletions of homopolymeric regions, or polymorphism, or microsatellite instability within the defined target regions, or
 - 10 - identifying the structural variations within the undefined target regions, or
 - quantifying the number of distinct targets within the DNA sample.
2. The method of claim 1, wherein the barcode sequence is an oligonucleotide comprising 10 to 16 random nucleotides, or 10 to 15 random nucleotides, or 10 to 13
15 random nucleotides, or 10 random nucleotides, or 11 random nucleotides, or 12 random nucleotides, or 13 random nucleotides, or 14 random nucleotides, or 15 random nucleotides, or 16 random nucleotides.
3. The method of claim 1 or 2, wherein the barcode sequence is an oligonucleotide
20 comprising 10 random nucleotides.
4. The method of any one of the preceding claims, wherein the primer A, the primer B, the primer C and/or the double stranded oligonucleotide further comprises an adapter sequence.
- 25 5. The method of any one of the preceding claims, wherein the structural variation is selected from the group consisting of deletion, duplication, insertion, inversion, transversion, and translocation.
- 30 6. The method of any one of the preceding claims, wherein the sequencing result is further used to detect a point mutation within the undefined target regions.
7. The method of any one of the preceding claims, wherein step o further comprises:

- a. grouping the sequencing results wherein the barcodes are identical into a subgroup;
 - b. comparing the sequencing results within the subgroup thereby determining a consensus sequence;
 - 5 c. mapping the consensus sequence to a reference sequence; and
 - d. identifying differences between the consensus sequence and the reference sequence.
- 10 8. The method of any one of the preceding claims, wherein the length of the target-specific sequence A, the target-specific sequence B, and/or the target-specific sequence C is from 17 nucleotides to 31 nucleotides, or from 19 nucleotides to 29 nucleotides, or from 20 nucleotides to 28 nucleotides, or from 21 nucleotides to 27 nucleotides, or from 22 nucleotides to 26 nucleotides, or 16 nucleotides, or 17 nucleotides, or 18 nucleotides, or 19 nucleotides, or 20 nucleotides, or 21 nucleotides,
15 or 22 nucleotides, or 23 nucleotides, or 24 nucleotides, or 25 nucleotides, or 26 nucleotides, or 27 nucleotides, or 28 nucleotides, or 29 nucleotides, or 30 nucleotides.
 - 20 9. The method of any one of the preceding claims, wherein the separation molecule is selected from the group consisting of biotin, digoxigenin (DIG), and Fluorescein isothiocyanate (FITC).
 10. The method of any one of the preceding claims, wherein the separation molecule is biotin.
 - 25 11. The method of any one of the preceding claims, wherein the bead that binds the separation molecule comprises streptavidin, anti-digoxigenin, or anti-FITC.
 12. The method of any one of the preceding claims, wherein the bead that binds the separation molecule comprises streptavidin.
 - 30 13. The method of any one of the preceding claims, wherein the DNA sample is obtained from a subject having and/or suspected of having a disease.

14. The method of claim 13, wherein the disease is cancer or infectious disease.
15. The method of claim 14, wherein the cancer is selected from the group consisting of lung cancer, colorectal cancer, breast cancer, pancreatic cancer, prostate cancer,
5 nasopharyngeal cancer, liver cancer, cholangiocarcinoma, esophageal cancer, urothelial cancer, and gastrointestinal cancer.
16. The method of claim 14, wherein the infectious disease is viral infection and bacterial infection.
- 10 17. The method of any one of the preceding claims, wherein the DNA sample is a liquid sample, a tissue sample, or a cell sample.
- 15 18. The method of claim 17, wherein the liquid sample is bodily fluids selected from the group consisting of blood, bone marrow, cerebral spinal fluid, peritoneal fluid, pleural fluid, lymph fluid, ascites, serous fluid, sputum, lacrimal fluid, stool, urine, saliva, ductal fluid from breast, gastric juice, and pancreatic juice.
19. The method of claim 18, wherein the bodily fluid is blood.
- 20 20. The method of claim 17, wherein the tissue sample is a frozen tissue sample or a fixed tissue sample.
- 25 21. The method of any one of the preceding claims, wherein the length of the DNA fragment A and/or the DNA fragment B is from 80 base pairs to 220 base pairs, or from 90 base pairs to 210 base pairs, or from 100 base pairs to 200 base pairs, or from 110 base pairs to 190 base pairs, or from 120 base pairs to 180 base pairs, or from 130 base pairs to 170 base pairs, or from 140 base pairs to 160 base pairs, or about 80 base pairs, or about 90 base pairs, or about 100 base pairs, or about 110 base pairs, or about
30 120 base pairs, or about 130 base pairs, or about 140 base pairs, or about 150 base pairs, or about 160 base pairs, or about 170 base pairs, or about 180 base pairs, or about 190 base pairs, or about 200 base pairs, or about 210 base pairs, or about 220 base pairs.

22. The method of any one of the preceding claims, wherein the length of the DNA fragment A and/or the DNA fragment B is about 150 base pairs.

23. The method of any one of the preceding claims, wherein the amount of DNA sample is from 10ng to 200ng, or from 20ng to 190ng, or from 30ng to 180ng, or from 40ng to 170ng, or from 50ng to 160ng, or from 60ng to 150ng, or from 70ng to 140ng, or from 80ng to 130ng, or from 90ng to 120ng, or from 100ng to 110ng, or about 10ng, or about 20ng, or about 30ng, or about 40ng, or about 50ng, or about 60ng, or about 70ng, or about 80ng, or about 90ng, or about 100ng, or about 110ng, or about 120ng, or about 130ng, or about 140ng, or about 150ng, or about 160ng, or about 170ng, or about 180ng, or about 190ng, or about 200ng.

24. The method of any one of the preceding claims, wherein the amount of DNA sample is about 100ng.

25. The method of any one of the preceding claims, wherein the DNA sample is selected from the group consisting of a eukaryotic DNA sample, a prokaryotic DNA sample, a viral DNA sample, and a mixture thereof.

26. The method of any one of the preceding claims, wherein the prokaryotic DNA sample is a bacterial DNA sample.

27. The method of any one of the preceding claims, wherein the eukaryotic DNA sample is selected from the group consisting of a protozoa DNA sample, a fungal DNA sample, an algae DNA sample, a plant DNA sample, and an animal DNA sample.

28. The method of claim 27, wherein the animal DNA sample is a mammalian DNA sample.



29. The method of claim 28, wherein the mammalian DNA sample is a human DNA sample.

30. The method of any one of the preceding claims, wherein the DNA sample is a cell free DNA or DNA of a lysed cell.



31. A kit comprising a plurality of primer A as defined in claim 1, a plurality of primer B as defined in claim 1, a plurality of primer C as defined in claim 1, a bead that binds the separation molecule as defined in claim 1, and a double stranded oligonucleotide as defined in claim 1.

32. The kit according to claim 31, wherein the kit further comprises a DNA polymerase, a Taq polymerase, a ligase, and a plurality of deoxyribonucleotide triphosphate (dNTPs).



1/20

**Figure 1a**

2/20

**Figure 1b**

3/20

**Figure 1c**





Figure 1d









Figure 1e



6/20

**Figure 1f**




Figure 2a

8/20




Figure 2b




Figure 3a




Figure 3b

Variant	0% VAF		0.1% VAF		1% VAF		5% VAF	
	Expected	Observed	Expected	Observed	Expected	Observed	Expected	Observed
EGFR								
E746_A750delELRA	0.00	0.00	0.10	0.06	1.00	1.79	5.00	6.50
EGFR								
L858R	0.00	0.00	0.10	0.12	1.00	0.62	5.00	6.07
EGFR								
T790M	0.00	0.00	0.10	0.04	1.00	0.17	5.00	3.21
EGFR								
V769_D770insASV	0.00	0.00	0.10	0.14	1.00	1.38	5.00	7.20
KRAS								
G12D	0.00	0.00	0.10	0.06	1.00	0.87	5.00	4.38
NRAS								
A59T	0.00	0.00	0.10	0.05	1.00	0.53	5.00	6.27
NRAS								
Q61K	0.00	0.00	0.10	0.16	1.00	1.23	5.00	8.14
PIK3CA								
E545K	0.00	0.00	0.10	0.12	1.00	2.15	5.00	7.26
Average	0.00	0.00	0.10	0.09	1.00	1.09	5.00	6.13
SD	0.00	0.00	0.00	0.05	0.00	0.67	0.00	1.61

Figure 4a




Figure 4b

Variant allele frequency		0.10 %		1 %		5 %	
Mutation Class	SNVs	Sensitivity >67%	Specificity >99%	Sensitivity >99%	Specificity >99%	Sensitivity >99%	Specificity >99%
	INDELs	>99%	>99%	>99%	>99%	>99%	>99%

Figure 4c




Figure 5

5' ACACGACGCTCTTCGATCTNNNNNNNNNNGGTGACCTTGTCTCTGTGTTTC-----extension-----
Target: 3' CCAC TGGG AACAGACAGACACAAAGaacaggggggtcgaacacctcggaggaatgtgggtca-

Figure 6

P-OATCGGAAAGCACACCTTC-3'
|||||
T⁺CTAGCCTTCTCGTGTGCAG-5'

Figure 7

5' ACACGACGCTCTTTCCGATCTNNNNNNNNNNNGGTGACCCCTTGTCTGTGTTCTGTCGAAcaccctcggagaaatgtgggtcacctctttcagat cctaaagaccacacgtc
 3' CCACTGGGACAGAGACACACAGcagcttgtggagcctctttacaccagtggaagagttctagcccttctcgtgttcacg

Figure 8a

5' ACACGACGCTCTTTCCGATCTNNNNNNNNNNNGGTGACCCCTTGTCTGTGTTCTGTCGAAcaccctcggagaaatgtgggtcacctctttcagat cctaaagaccacacgtc
 TGTGCTGGAGAGGCTAGGANNNNNNNNNNCCCACTGGGACAGAGACACAGcagcttgtggagcctctttacaccagtggaag----- TCTAGCCTTCTCTGTTGACG

Figure 8b

5' AATGATACGGGACACACCGAGATCTACACTCTTTCCCTACACGAGGCTCTTCCGATCTNNNNNNNNNNNGGTGACCCCTTGTCTGTGTTCTGTCGaaacacc
 tcggagaaatgtgggtcacctctttcagatccgagagacacacgtctgaaactccagtcacccgtgatatcttcgtatgcccgcttctcgtttg 3'

Figure 9




Figure 10a




Figure 10b




Figure 11a




Figure 11b




Figure 12




Figure 13




Figure 14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SG2019/050317

A. CLASSIFICATION OF SUBJECT MATTER**C12Q 1/6869 (2018.01)**

According to International Patent Classification (IPC)

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

FAMPAT/BIOSIS/MEDLINE: sequencing, structural variation, linear amplification, separate, pool, overhang, target and similar terms

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y A	WO 2016/081798 A1 (CHILDREN'S MEDICAL CENTER CORPORATION) 26 May 2016 <i>Whole document, in particular Fig. 1A & Para. [00246]-[00253]</i>	31 AND 32 1-30
Y A	HU J. ET AL., Detecting DNA Double-Stranded Breaks in Mammalian Genomes by Linear Amplification-mediated High-Throughput Genomewide Translocation Sequencing (LAM-HTGTS). <i>Nat Protoc</i> , May 2016, Vol. 11, No. 5, pages 853-871 [Retrieved on 2019-08-26] <DOI: 10.1038/NPROT.2016.043> <i>Whole document, in particular Fig. 1b & Experimental design</i>	31 AND 32 1-30
Y	WO 2015/200541 A1 (BIO-RAD LABORATORIES, INC.) 30 December 2015 <i>Para. [0172]</i>	31 AND 32
Y	Illumina, "TruSeq® DNA Library Prep Kits". 17 November 2014 [Retrieved on 2019-08-26 from https://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/datasheet_truseq_dna_sample_prep_kits.pdf] <i>Fig. 2D; Innovative Library Preparation Chemistry</i>	31 AND 32

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

*Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

26/08/2019

(day/month/year)

Date of mailing of the international search report

28/08/2019

(day/month/year)

Name and mailing address of the ISA/SG

**Intellectual Property Office of Singapore**

1 Paya Lebar Link, #11-03

PLQ 1, Paya Lebar Quarter

Singapore 408533

Email: pct@ipos.gov.sg

Authorized officer

Sung Ying Ying (Dr)

IPOS Customer Service Tel. No.: (+65) 6339 8616

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SG2019/050317

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☐ forming part of the international application as filed:
 - ☐ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13~~ter~~.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
 - ☐ in the form of an Annex C/ST.25 text file (Rule 13~~ter~~.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13~~ter~~.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

Although a sequence listing has been filed or furnished, it was not used for the purposes of this search.

Since only one version or copy of a sequence listing has been filed or furnished, the statements under item 2 are not required.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SG2019/050317

Note: This Annex lists known patent family members relating to the patent documents cited in this International Search Report. This Authority is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2016/081798 A1	26/05/2016	EP 3221813 A1 US 2018/0346977 A1	27/09/2017 06/12/2018
WO 2015/200541 A1	30/12/2015	CN 105392902 A HK 1219116 A1 EP 3161157 A1 US 2016/0060621 A1	09/03/2016 24/03/2017 03/05/2017 03/03/2016